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Abstract
The overall objective of this project was the development of a systematic approach for
identifying potential interactions between plant-based food and marketed psycholeptics
and psychoanaleptic drugs. The problem was addressed, initially, by pairing psychiatric
agents and phytochemicals to their common protein targets, using information available
in online databases, such as NutriChem 1.0 [21] and Drugbank [16] and constructing the
food-drug interaction networks. Thereupon, a search for additional phytochemicals that
would be expected to interact with targets of psychiatric drugs was carried out. More
specifically, three protein targets, P07550, P28222 and P14416 were selected, based on
their frequency of interactionwith both psycholeptics and psychoanaleptics and the avail-
ability of 3D structural information in PDB [19]. For these protein targets, ligand-based
pharmacophoric hypothesis were generated, using experimental activity data from the
literature, and the HypoGen feature of Accelrys Discovery Studio (DS) [7]. The phar-
macophore models were validated using external test sets and Fisher’s method. Sub-
sequently, the models were used as queries to screen the NutriChem 1.0 database for
more potentially active phytochemicals. Finally, based on a protocol introduced by Vi-
lar et al. [37], a similarity-based prediction of psychiatric drugs’ interactions with nutri-
ents, present in plant-based food, was carried out. For that purpose, a reference database
was constructed, incorporating information about 1763 FDA approved drugs and 69,356
drug-drug interactions (DDIs). Drug-drug interaction profile similarity, adverse effects
similarity information, as well as 2D structural and target similarity information was
gathered for the reference data set and used to train a SVM classification model. This
model was later used to predict interactions between 64 phytochemicals and 85 psychi-
atric drugs.
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Chapter 1
Introduction
1.1 Determining drug and plant-based food interactions
Diet constitutes one of the most dynamic expressions of the ”exposome”, a term used
to describe the sum of all environmental exposures (e.g. diet, air pollutants, lifestyle fac-
tors) over the life course of an individual (Jensen et al. [21]). Moreover, it is one of the
most challenging to assess its effects in health homeostasis and disease development,
considering its myriad components and their temporal variation. Through anecdotal ex-
perience, vegetables and fruits are considered beneficial to our health. Indeed, it is esti-
mated that almost 80% of chronic diseases could be avoided by consumption of healthier
food, whereas meta-analysis of observational studies has shown a dose-response effect
of fruits and vegetables on cardiovascular diseases and stroke risk (Jensen et al. [21]). In
several diseases the treatment effect is augmented by the combination of certain dietary
components with pharmacotherapy. However, interference of plant-based foods with
drug performance and pharmacological activity may also potentially contribute to an
increased risk of side effects or treatment failure. Enzyme-inducing antiepileptic drugs
such as carbamazepine and phenytoin may decrease serum vitamin D concentration by
increasing the metabolism of vitamin D. An association among their use, reduced bone
mineral density, and increased fracture risk has been suggested by several observational
studies.(Chan [10]). In some cases drug intake may cause a negative impact on nutri-
ent homeostasis, although the opposite can also happen; changes in nutrient intake can
1
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significantly alter a patient’s response to a drug. A well-known example of an unfa-
vorable drug-food interaction, the inhibitory effect of grapefruit juice on cytochrome
P450, results in increased bioavailability of drugs such as felodipine, cyclosporine and
saquinavir, which could lead to drug toxicity and poisoning (Jensen et al. [22]).
The causes of drug-food interactions are multifactorial and can also depend on sex,
ethnicity, environmental factors, and genetic polymorphisms (Chan [10]). The majority
of high risk treatment failure due to drug-food interactions is associated with reduced
bioavailability of the drug in the fed state. Possible explanations include chelation with
components in food, gastric acid secretion during food intake, or other direct drug-food
interactions. On other occasions, food intake may result in an increase in drug bioavail-
ability either because of a food-induced increase in drug solubility or because of the
secretion of gastric acid or bile in response to food intake. In those cases, the effect of
increased bioavailability of the drug tend to be ambiquous (Schmidt LE [36]).
Since drug-food associations are well recognized as an important element in pharma-
ceutical treatment, a need arises to systematically identify, predict and manage potential
interactions between food and and marketed or novel drugs. Such an approach would
pave the way for further applications in personalized medicine.
1.1.1 Definition of a drug-nutrient interaction
A drug-nutrient interaction, often referred to as a drug-food interaction, is defined
as a physical, chemical, physiologic, or pathophysiologic relationship between a drug
and a nutrient (Chan [10]). Assessing the dietary intervention in drug therapy can be
better founded in a nutrient-based approach, as it allows for a more effective understand-
ing of its mechanism. Additionally, clinical significance is noted when a drug-nutrient
interaction becomes associated with an altered physiologic response, which may lead
to malnutrition, treatment failure, adverse events, or, in the most serious case, a life-
threatening event, including death (Chan [10]). Drug-nutrient interactions are often as-
sociated with a quantifiable alteration of the pharmacokinetic and/or ppharmacodynamic
profile of a drug or a nutrient. The term kinetics (pharmacokinetics, nutrikinetics) refers
to the quantitative description of the disposition of a drug or nutrient in the human body,
through the processes of absorption, distribution, metabolism, and excretion of the com-
2
1.1. Determining drug and plant-based food interactions
pound (ADME)(Chan [10]). Based on the physiological sequence of events after a drug
or nutrient has entered the body and the subsequent mechanism of interaction Chan [10]
identified four broad categories of interactions; I. Ex Vivo Bioinactivations: This type of
interactions involves chemical or physical reactions that take place before the drug and
nutrient involved have entered the body (eg. in enteral nutrition or parenteral nutrition).
II. Absorption Phase–Associated Interactions: Here, the nutrient may modify the func-
tion of an enzyme (type A interaction) or a transport protein (type B interaction) that is
responsible for the biotransformation or transport of the drug prior to reaching the sys-
temic circulation. According to the norm, many type II interactions can be avoided by
allowing an adequate amount of time between drug intake and the consumption of the
nutrient. III. Physiologic Action–Associated Interactions: There interactions occur after
the absorption phase is complete for at least 1 of the interaction pairs. The mechanisms
involve changing the cellular or tissue distribution, systemic metabolism or transport,
or penetration to specific organs or tissues of the nutrient/drug (pharmacodynamic alter-
ations). On this occasion, separation of administration times is not expected to resolve
the problem. IV. Elimination Phase–Associated Interactions: These interactions may in-
volve the modulation, antagonism, or impairment of renal or enterohepatic elimination.
1.1.2 Obstacles in identifying and predicting herbal-drug interac-
tions
The task of adverse events reporting for interactions, positive or negative, between
drugs and plant-based food is challenging, even for those phytochemicals that are already
marketed as nutraceuticals or dietary supplements. A report published by the Department
of Health and Human Services (DHHS) estimated that less than 1% of all drug – dietary
supplement interactions are reported to the FDA through the MedWatch system for re-
porting adverse events(Chavez et al. [11]). Moreover, in a published systematic review,
aiming to assess the interactions between herbal and conventional drugs (Fugh-Berman
and Ernst [18]), it was found that only 13% of the suspected interactions that were ex-
tracted from online databases and evaluated, could be characterized as well-documented.
The existing data that guide the clinical management of most drug-nutrient interactions
3
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are mostly anecdotal experience, uncontrolled observations, and opinions, whereas the
science in understanding the mechanism of drug- nutrient interactions remains limited.
This scarcity of published clinical evidence constitutes a major setback in the process of
identifying and predicting herbal-drug interactions.
Another barrier in identifying potential interactions resides in the nature of plant-based
food, itself. First of all, natural products usually consist of complex mixtures of bioactive
compounds, whose exact chemical composition is often unknown. Further complicating
the matter, the chemical constituents of plant-based food may vary according to the sea-
sonality, growing conditions, or the specific part of the plant that is examined. For herbal
dietary supplements, the variation in manufacturing processes, which are not standard-
ized, nor regulated by the FDA, augments the overall complexity, as well (Chavez et al.
[11]).
1.1.3 Overview of available methods
Known or suspected pharmacological activity, data derived from in vitro or animal
studies, or isolated case reports are the common sources for gaining knowledge on the
interference of dietary components with the pharmacokinetics and/or pharmacodynamic
processes of medical substances (Chavez et al. [11]). However, the scarcity of clinical
based evidence, combined with the frequent lack of comprehensive documentation, un-
derlines the importance of using data mining computational techniques for effective ex-
traction of large scale, relevant information and, furthermore, stresses the potential of
developing in silico models for the prediction of unwanted side effects (SEs), caused
by the intervention of phytochemicals with drug protein targets. In this respect, several
SE prediction, systems biology computational methods that are widely employed in the
pharmaceutical industry to predict drug-drug interactions (DDIs), such as pathway based
methods or chemical similarity based methods, might also prove to be pertinent in pre-
dicting drug-food interactions. A recently published study by Jensen et al. [22] presented
a systems chemical biology approach that integrated data from the scientific literature
and online databases, to gain a global view of the associations between diet and dietary
molecules with drug targets, metabolic enzymes, drug transporters and carriers currently
deposited in DrugBank. Additionaly ,disease areas and drug targets that are most prone
4
1.2. Psycholeptic and Psychoanaleptic drugs
to the negative effects of drug-food interactions were identified, showcasing a platform
for making recommendations in relation to foods that should be avoided under certain
medications. Lastly, by investigating the correlation of gene expression signatures of
foods and drugs novel drug-diet interactome map was generated.
1.2 Psycholeptic and Psychoanaleptic drugs
Since the discovery of the first psychiatric drugs, more than 50 years ago, pharmaceuti-
cal companies have been regarding psychopharmaceuticals as a major part of the overall
prescription drug market. Although many efforts have been invested in discovering an-
tidepressant, anxiolytic or antipsychotic agents with new, alternative, mechanisms of
action, the original mechanisms on monoamine or GABAergic systems remain the basis
of all currently available drugs. New approaches to discover new, cognitive enhancing,
drugs, among many different ideas, have attempted to enhance cholinergic function, us-
ing selectivemuscarinic or nicotinic agonists. Other approaches include the development
of selective dopamine D1 receptor agonists, or drugs that alter glutamatergic function by
suppressing NMDA or AMPA receptor function (Iversen [20]). In the present study, two
main subcategories of psychopharmaceuticals are examined for their interactions with
plant-based food; the psycholeptics and the psychoanaleptics.
In pharmacology, a psycholeptic is a tranquilizer, or a medication which produces a
calming effect upon a person. The psycholeptics are classified under N05 in the Anatomi-
cal Therapeutic Chemical Classification System (ATC), a system of alphanumeric codes
developed by theWHO for the classification of drugs and othermedical products. InATC
classification system, the active substances are divided into different groups according to
the organ or system on which they act and their therapeutic, pharmacological and chem-
ical properties. A psychoanaleptic, on the other hand, is a medication that produces an
arousing effect. The psychoanaleptics are classified under N06 in the Anatomical Thera-
peutic Chemical Classification System. Subcategories of N06 include Psychostimulants
(ex. amphetamines), agents used for ADHD, nootropics, anti-dementia drugs and antide-
pressants (for Drug Statistics Methodology [17], DS. et al. [16]).
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Table 1.1: ATC N05 Psycholeptics (DS. et al. [16])
PSYCHOLEPTICS
ANTIPSYCHOTICS HYPNOTICS AND SEDATIVES ANXIOLYTICS
Benzamides Phenothiazines with piperidine structure Aldehydes and derivatives Azaspirodecanedione derivatives
Sulpiride Propericiazine Dichloralphenazone Buspirone
Remoxipride Thioridazine Chloral hydrate Benzodiazepine derivatives
Amisulpride Pipotiazine Paraldehyde Oxazepam
Butyrophenone derivatives Mesoridazine Barbiturates, plain Lorazepam
Melperone Thioxanthene derivatives Barbital Adinazolam
Pipamperone Thiothixene Secobarbital Tofisopam
Droperidol Zuclopenthixol Talbutal Alprazolam
Haloperidol Chlorprothixene Pentobarbital Chlordiazepoxide
Diazepines, oxazepines, thiazepines and oxepines Flupentixol Thiopental Clobazam
Quetiapine Amobarbital Halazepam
Loxapine Aprobarbital Camazepam
Asenapine Butethal Ethyl loflazepate
Olanzapine Heptabarbital Cloxazolam
Clozapine Hexobarbital Bromazepam
Diphenylbutylpiperidine derivatives Methohexital Clotiazepam
Fluspirilene Benzodiazepine derivatives Fludiazepam
Pimozide Estazolam Ketazolam
Indole derivatives Midazolam Prazepam
Molindone Flurazepam Etizolam
Lurasidone Triazolam Diazepam
Sertindole Temazepam Carbamates
Ziprasidone Brotizolam Mebutamate
Lithium Flunitrazepam Meprobamate
Lithium Quazepam Dibenzo-bicyclo-octadiene derivatives
Other antipsychotics Cinolazepam Benzoctamine
Zotepine Nitrazepam Diphenylmethane derivatives
Aripiprazole Benzodiazepine related drugs Hydroxyzine
Paliperidone Eszopiclone Captodiame
Iloperidone Zolpidem Other anxiolytics
Risperidone Zaleplon Etifoxine
Cariprazine Zopiclone
Phenothiazines with aliphatic side-chain Melatonin receptor agonists
Acepromazine Melatonin
Promazine Ramelteon
Cyamemazine Other hypnotics and sedatives
Methotrimeprazine Ethchlorvynol
Chlorpromazine Methaqualone
Triflupromazine Triclofos
Phenothiazines with piperazine structure Scopolamine
Thioproperazine Propiomazine
Perphenazine Dexmedetomidine
Acetophenazine clomethiazole
Prochlorperazine Piperidinedione derivatives
Fluphenazine Methyprylon
Trifluoperazine Glutethimide
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Table 1.2: ATC N06 Psychoanaleptics (DS. et al. [16])
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS ANTIDEPRESSANTS ANTI-DEMENTIA DRUGS
Centrally acting sympathomimetics Desipramine Anticholinesterases
Amphetamine Protriptyline Galantamine
Pemoline Dosulepin Donepezil
Dextroamphetamine Other antidepressants Tacrine
Methamphetamine Oxitriptan Rivastigmine
Atomoxetine Tianeptine Other anti-dementia drugs
Lisdexamfetamine Venlafaxine Memantine
Methylphenidate Milnacipran Ginkgo biloba
Modafinil Nomifensine
Dexmethylphenidate Mianserin
Fencamfamine Vortioxetine
Fenethylline Reboxetine
Other psychostimulants and nootropics Agomelatine
Aniracetam Vilazodone
Acetylcarnitine Nefazodone
Adrafinil Duloxetine
Idebenone Bupropion
Piracetam Desvenlafaxine
Xanthine derivatives L-Tryptophan
Caffeine Minaprine
propentofylline Trazodone
Monoamine oxidase A inhibitors Mirtazapine
Toloxatone Viloxazine
Moclobemide Selective serotonin reuptake inhibitors
Monoamine oxidase inhibitors, non-selective Paroxetine
Iproclozide Zimelidine
Isocarboxazid Citalopram
Nialamide Sertraline
Tranylcypromine Fluoxetine
Phenelzine Escitalopram
Non-selective monoamine reuptake inhibitors Fluvoxamine
Nortriptyline Etoperidone
Amoxapine
Clomipramine
Trimipramine
Amineptine
Amitriptyline
Maprotiline
Dimetacrine
Imipramine
Butriptyline
Doxepin
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Chapter 2
Food Interaction Networks for
Psycholeptic and Psychoanaleptic
Drugs
2.1 Introduction
2.1.1 Assessing the pharmacodynamics and pharmacokinetics effects
of drug-food interactions through identification of shared pro-
tein targets
While attempting to assess the effects (positive or negative) of plant-based food on
the pharmacological action of drugs, a significant dichotomy is observed. Herbal–drug
interactions can be characterized as either pharmacodynamic (PD) or pharmacokinetic
(PK) in nature.
PK interactions imply an alteration of the absorption, distribution, metabolism, or elim-
ination properties (ADME) of a conventional drug by an herbal product. Understanding
ADME requires an insight in the bioavailability of the drug candidate from the route of
administration to the ultimate site of activity, for the required duration of time, in order
to elicit the intended pharmacology. On the first stages, factors that influence the absorp-
tion of a drug (usually for oral administration), are the dissolution and solubility within
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the gastrointestinal lumen, luminal behavior, enterocyte permeability, and intestinal and
liver metabolism. Later on, the distribution phase initiates, once the drug reaches the sys-
temic circulation. Thereupon, the intended ADME are dictated by plasma pharmacoki-
netics. On the final stage, the duration of drug activity is influenced by drug metabolism
and elimination (Dowty et al. [15]). In order to study the pharmacokinetics of drugs, the
interactions of phytochemicals with proteins involved with ADME (metabolic enzymes,
transporters, carriers) should be reviewed.
Pharmacodynamic (PD) interactions may occur when constituents of herbal products
have either synergistic or antagonist activity in relation to a conventional drug. As a
result, the bioavailability of a therapeutic molecule is altered at the site of action, at the
drug-receptor level. To get an insight of the pharmacodynamic processes that are affected
by a phytochemical, interactions with drug targets should be studied (Chan [10]).
2.2 Methodology
2.2.1 Data availability
There are not many available collections of resources, regarding the molecular compo-
sition of food and the related biological activities of its phytochemical content. Examples
of ongoing efforts include the Danish Food Composition Database, the Phenol-Explorer
[32], the KNApSAcK Family Database [1] and the MAPS database. However, a signif-
icant shortage of these databases, from a systems biology scope, is the lack of chemical
structures and high-throughput retrieval of data [21].
In order to better understand the association of phytochemicals with disease related
protein targets, the NutriChem database was utilized, developed by Jensen et al. [21], and
aiming to provide an exhaustive resource, listinig the molecular content of plant-based
food and the effects of dietary interventions. To build NutriChem, 21 millionMEDLINE
abstracts (1908-2012) were processed by text mining, to detect information concerning
links of plant - based food with its constituents and links of food with human disease
phenotypes. A Naive - Bayes classifier was trained to recognize these links and, sub-
sequently, validated using an external dataset of 250 abstracts, yielding an accuracy of
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88.4% in discovering food - phytochemical pairs and 84.5% for food - disease pairs. An
association of phytochemicals with disease on a molecular level ensued, by identifying
phytochemicals with experimental bioactivity against disease associated protein targets,
using ChEMBL database and the Fisher’s exact test to systematically discover associa-
tions from the mined data pairs of food - phytochemicals and food - diseases. This effort
resulted in a content of 18487 pairs of 1772 plant - based food and 7898 phytochem-
icals, along with 6442 pairs of 1066 plant - based foods and 751 diseases phenotypes.
Moreover, predicted associations were generated for 548 phytochemicals and 252 dis-
eases. The current version of NutriChem 1.0 database allows querying by plant- based
food name of id, by disease, or by phytochemical coumpound. In the present study, Nu-
triChem was used to construct the networks of drug - food space interactions, by ex-
tracting data concerning which phytochemicals interact with relevant drug targets and
in what plant - based food these phytochemicals can be found.
In order to construct the drug - protein target interaction network for psycholeptic and
psychoaanaleptics, data was extracted from the Drugbank database (DS. et al. [16]), in-
cluding information about primary and secondary human protein targets, enzymes, trans-
porters and carriers.
2.2.2 Data processing
To promote a broader understanding of the interactions between the plant-food space
and the drug space of psycholeptic and psychoanaleptic agents, the protein target net-
works were constructed.
The plant-based food compounds and their human protein targets were retrieved from
NutriChem 1.0 database . Thereupon, the matching of phytochemicals to their specific
plant-based food of origin was verified by manually curating the data retrieved from
NutriChem. This process was carried out by closely examining the references cited for
each food-compound pairing. Because of the innate characteristics of the algorithm used
to mine data from PubMed abstracts, a small number of false positive food-compound
pairings were observed. Those errors occurred usually for one of the following reasons:
• The reference text included an experimental assay of more than one plant-based
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foods. In that case the algorithm assigned the phytochemicals present in the text
to each and every plant-based food that was also mentioned.
• The phytochemicals were associated with parts of the plant-based food that are not
edible. For example Serotonin was mentioned to be present in leaves and seeds of
the Solanum tuberosum, but not in the tubers, which are the edible part of the
potato.
• The mined text referred to an experimental assay testing a plant-based food for
specific compounds of interest, and concluded that they were not found in the
plant.
• The chemical compound was artificially added and used as part of a pretreatment
method for an experimental assay.
It is noted that all proteins in the interactions networks are represented by their Uniprot
ID [13], all drugs are mentioned by their Drugbank codes [16], and finally, all plant-
based food is cited by its id in NCBI Food Taxonomy (http://www.ncbi.nlm.nih.
gov/Taxonomy/taxonomyhome.html/index.cgi?chapter=advisors) . The full data
tables for the networks are attached as supplementary material S7 and S8.
2.3 Drugs to protein target interactions network
In order to construct the drug - protein target interaction network for psycholeptic and
psychoanaleptics, data was extracted from the Drugbank database (DS. et al. [16]), in-
cluding information about primary and secondary human protein targets, enzymes, trans-
porters and carriers. The pharmacological action of each drug-protein pair was either
known, or unknown.
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Figure 2.1: Network mapping of psycholeptic drugs to their human protein targets, en-
zymes, transporters and carriers. Node size is proportionate to the degree of connectivity
for each node.
A total of 77 psycholeptic drugs were found to be interacting with a summation of 191
unique protein targets. Among the proteins, 7 transporters, 141 targets, 3 carriers and 40
enzymes could be identified. In Figure 2.1 the interaction network is presented. In this
graph it becomes apparent that two major subcategories of drugs can be distinguished,
based on their targeting of different human proteins targets. The first one occupies the
left, lower, subset area of the network, and comprises mostly of antipsychotic agents,
while the second one occupies the right subset area, and is made up of anxiolytics, hyp-
notics and sedatives. However, most of the enzymes,carriers and transporters are located
roughly in the middle of the interaction network, indicating that they are targeted often
by antipsychotics, anxiolytics, hypnotics and sedatives, alike.
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Figure 2.2: Network mapping of psychoanaleptic drugs to their human protein targets,
enzymes, transporters and carriers. Node size is proportionate to the degree of connec-
tivity for each node.
Next, the ATC N06 subcategory of 57 psychoanaleptic drugs was matched to 246
human proteins, of which, 13 were transporters, 3 carriers, 41 enzymes and 189 protein
targets. The interaction network for psychoanaleptics is presented in Figure 2.2. While
observing the networks, it is noted that several proteins can qualify as targets of both
psycholeptic and psychoanaleptic drugs.
2.4 Food to protein target interactions network
Several constituents of plant-based food were found to be active against some of the
protein targets of psycholeptic and psychoanaleptic drugs that were mentioned above.
The network mapping of plant-based food to their human protein targets was carried
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out, including only the protein targets, enzyme, carriers and transporters that were also
targeted by psycholeptic or psychoanaleptic drugs.
For psycholeptic drugs, 12 protein targets and 1 metabolic enzyme (P06276) were also
targeted by a variety of plant-based food nutrients. As each food node is connected with
a protein node by more than one edges, forming a multigraph, it is apparent that some
foods may interfere with psycholeptic drugs by means of multiple protein-nutrient in-
teractions. The most commonly targeted protein by nutrients is the enzyme P06276 or
human Cholinesterase BCHE, an esterase with broad substrate specificity that is known
to contribute to the inactivation of the neurotransmitter acetylcholine. It can, also, de-
grade neurotoxic organophosphate esters [13]. Sorting the protein nodes by degree of
connectivity, proteins P49841 and P21728 emerged as the next most common proteins
targeted by food. Figure 2.3 illustrates the food-protein network for psycholepic drugs.
It is worth noting that the proteins often targeted by phytochemicals do not coincide with
popular protein targets in the network of psycholeptics, and furthermore, most of them
target proteins related to antipsychotic drugs, rather than sedatives/ anxiolytics .
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Figure 2.3: Network mapping of plant-based food (yellowmarked nodes) to their human
protein targets (greenmarked nodes). Included are only the protein targets, enzyme, carri-
ers and transporters that are also targeted by psycholeptic drugs. Different colored edges
represent different active compounds contained in plant-based food.
The equivalent network for psychoanaleptic drugs features 21 protein targets and 2
metabolic enzymes (P27338, P06276). Furthermore, the proteins most commonly tar-
geted by phytochemicals are P22303, P21728, P06276, P41143 and P41145. Figure 2.4
illustrates the food-protein network for psychoanalepic drugs.
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Figure 2.4: Network mapping of plant-based food (yellowmarked nodes) to their human
protein targets (green marked nodes). Included are only the protein targets, enzyme, car-
riers and transporters that are also targeted by psychoanaleptic drugs. Different colored
edges represent different active compounds contained in plant-based food.
2.5 The drug - food space interaction network
All the available data can be combined in the construction of the food-drug space
interaction networks in Figures 2.5 and 2.6. Most of these interactions indicate possible
alterations of the pharmacodynamic properties, since they mostly revolve around protein
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targets, and less around transporters, carriers or metabolic enzymes. Additionally, not all
proteins that are co-targeted by phytochemicals have a known pharmacological action
for the drugs in question.
In Figure 2.5 a large subgroup of psycholeptic drugs is predicted to interact with sev-
eral herbal dietary components, whereas a smaller subgroup is found to be targeted
only by 3 plant-based foods; safflower (TAXID:4222),tomato (TAXID:4081) and gar-
lic (TAXID:4682). Those are also the foods with the higher degree of connectivity in
the entire graph, interacting with the majority of psycholeptic drugs, through multiple
proteins.
In Figure 2.6 two subcategories of food nodes are distinguished. The first one, featur-
ing strawberry (TAXID:3747), onion (TAXID:4679), quinces (TAXID:36610), sweet-
pepper (TAXID:4072) and swede (TAXID:3708), among others, seems to interactmainly
with a group of 8 psycoanaleptics (DB00382, DB00989, DB00370, DB08996, DB00321,
DB00543, DB00674, DB00805, DB00726). The second one, where ginger (TAXID:94328),
poppy-seed (TAXID:3469)and safflower (TAXID:4222) are the most prominent, shares
protein targets with all drugs in the network.
In Figures 2.7 and 2.8 the complete interaction networks are demonstrated. The pro-
tein targets in these graphs are all targeted by food nutrients and drugs, alike. However,
different topologies are present in the graphs, where targets are mostly interacting with
food, as opposed to drugs, and vice versa.
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Figure 2.5: Drug to plant-based food interaction network, where each edge represents a
common protein target between a psycholeptic drug and a phytochemical, belonging to
an edible plant. Node size is proportionate to the connectivity degree of the node. All
edges have been bundled in order to obtain a clear, representative image of the dense
network. Marked red are the edges that signify a known pharmacological action of the
drug on the protein target.
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Figure 2.6: Drug to plant-based food interaction network, where each edge represents a
common protein target between a psychoanaleptic drug and a phytochemical, belonging
to an edible plant. Node size is proportionate to the connectivity degree of the node. All
edges have been bundled in order to obtain a clear, representative image of the dense
network. Marked red are the edges that signify a known pharmacological action of the
drug on the protein target.
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Figure 2.7: Network mapping of psycholeptic drugs and plant-based food to the human
proteins that they target. Node size indicates the degree of connectivity of each node.
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Figure 2.8: Network mapping of psychoanaleptic drugs and plant-based food to the hu-
man proteins that they target. Node size indicates the degree of connectivity of each
node.
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Chapter 3
Pharmacophores for phytochemicals
interacting with psychiatric drug
targets
3.1 Introduction
In the next part of this study, a search for additional phytochemicals that would be
expected to interact with targets of psychiatric drugs was carried out. More specifically,
three protein targets, P07550, P28222 and P14416 were selected, based on their fre-
quency of interaction with both psycholeptics and psychoanaleptics and the availability
of 3D structural information in PDB. For these protein targets, ligand-based pharma-
cophoric hypothesis were generated, using experimental activity data from the literature
(ChEMBL database), and the HypoGen feature of Accelrys Discovery Studio (DS). The
pharmacophore models were validated using external test sets and Fisher’s method to
evaluate the ability of pharmacophores to differentiate between experimentally known
actives. Finally, the valid pharmacophores were used as queries to screen for more po-
tentially active phytochemicals from the NutriChem 1.0 database.
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3.1.1 Storing 3D structures
A fundamental problem in Chemoinformatics is the lack of a priori information avail-
able, that would reveal what the 3D structure of a compound would be. Moreover, all
compounds are flexible to some degree, so the 3D structure might change over time. Ex-
perimental 3D structure data, derived either from X-ray crystallography or NMR spec-
troscopy, can only get us so far, and they are often unable to predict the form that the com-
pound will take for example when binding to a protein target. Instead, computational 3D
flexibility analysis can be employed to tackle this problem [43]. Most compounds have
rotatable bonds, which means that the whole molecule can flex into many different poses
in 3D, which are referred to as different ”conformers”. An empirical definition for a ro-
tatable bond is: any single bond which is not part of a ring, is not terminal (e.g. Methyl)
and is not in a conjugated system (e.g. an Amide). It is understood that a single molecule
can have an infinite or less than infinite number of conformers (if discrete rotation units
are considered). Conformers of a compound can be unequal in regard to their energy
levels, and usually the most low energy (and thus stable) conformers are encountered.
Conformation flexibility can be dealt with either at the representation level, by storing
multiple conformers, or at the algorithm level, by providing just one representation of
the 3D structure and letting algorithms flex the molecule as needed [43]. While only in-
formation about the atoms and how they are connected by bonds is required in order to
store 2D structural data, the coordinates of atoms relative to some origin and conforma-
tion analysis is additionally required to create 3D databases. Usually a connection-table
type file format, often either an MDL MOL or SD File or a Sybyl MOL2 file is used to
store 3D structural information. Other formats can be used too, such as CML, PDB and
for the coordinates simply an XYZ file [43].
3.1.2 QSAR and Virtual Screening
QSAR stands for Quantitative Structure-Activity Relationships. It refers to the mathe-
matical correlation of structural features with experimental activity results, for multiple
compounds, usually in the same series. Biological activity is then translated into a func-
tion of molecular descriptors (structural or physicochemical properties). If the model
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generated is successful, we can use this function as a predictive tool for compounds,
where the activity is unknown, but the descriptors can be calculated. QSARmay assume
linear, or non linear functions to describe activity. When non linear QSAR is carried
out, methods such as Neural Networks, Decision Trees, Support Vector Machines or
Bayesian classifiers can be employed [43].
One very common application of QSAR models, particularly nonlinear models is in
virtual screening. This means using informatics to predict which of a large number of
compounds will bind to a protein target or inhibit a cellular assay. It is, in other words,
a computational equivalent to high throughput biological assaying. Other methods, al-
ternative to QSAR for virtual screening, include simple chemical similarity to known
active compounds, and molecular docking when protein target structure information is
available. When QSAR methods are used for virtual screening, it is common to use
classification models, that discern between active and inactive compounds, as well as
quantitative prediction models (which attempt to predict a strength of binding) [43].
3.1.3 Pharmacophores
A pharmacophore is a generic set of molecular features that is required for binding to
a biological macro-molecule. It is used to refer to structural features (or derivatives such
as hydrogen bonding potential), and is usually used in reference to 3D structures. It may
also be defined as set of features and distance bounds of these features from each other in
3D [43]. It does not represent a real molecule or a real association of functional groups,
but a purely abstract concept that accounts for the common molecular interaction capac-
ities of a group of compounds towards their targets structure. Thus, a pharmacophore
represents chemical functions, valid not only for one currently bound ligand, but also
for unknown molecules [42].
A pharmacophore can be represented in a variety of ways: e.g. a distance matrix of
pharmacophore points (with a dictionary for point types which may contain coordinates
of 3D substructures or SMARTS of 2D features). The generic structure described by the
pharmacophore needs to able to represent distance ranges (rather than exact ranges) and
incorporate ambiguity in pharmacophore points [43]. Pharmacophoric features can be
defined in the 2D or 3D space. When 2D pharmacophores are used, the information con-
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cerning the relative position of features can be stored as a pharmacophore fingerprint
(1D vector storing relative distances between the features). Common pharmacophore
features include the H-bond acceptor, H-bond donor, anionic, cationic, hydrophobic and
aromatic features. An atom is considered an acceptor if it can attract an hydrogen (ni-
trogen, oxygen or sulfur and not an amide nitrogen, aniline nitrogen and sulfonyl sulfur
and nitro group nitrogen), and a donor if it can give an hydrogen [34].
A pharmacophore can be used as a potent tool in virtual screening, to query 3D databases
of compounds, in order to find molecules that bind to a particular protein. A pharma-
cophore search resembles a substructure search, as it comprises of a sub-graph query on
a fully-connected distance matrix graph [43]. It can be used to filter a ligand database,
prior to docking simulations, or as a post filtering tool of docking results to remove com-
pounds that don’t bind according to the pharmacophore query. Moreover, the pharma-
cophore alignment can be used to guide the placement during a docking session. Other
applications of pharmacophores include target identification, prediction of drug side-
effects, ADME-tox profiling and 3D QSAR analysis [34].
An instance of pharmacophore based virtual screening was applied in the early stages
of drug discovery for alternatives to Rimonabant. Rimonabant is an anorectic anti-obesity
drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabi-
noid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the
first selective CB1 receptor blocker to be approved for use anywhere in the world. It is ap-
proved in 38 countries including the E.U., Mexico, and Brazil. However, it was rejected
for approval for use in the United States. This decision was made after a U.S. advisory
panel recommended themedicine not be approved because it may increase suicidal think-
ing and depression [16]. During the lead discovery of alternatives for Rimonabant, com-
pounds were examined as potential cannabinoid receptor CB1 antagonists. The cannabi-
noid receptor’s crystal structure was yet unknown and only some homologymodels were
available in the literature. In order to build the pharmacophore for CB1, 8 CB1 selective
antagonists/inverse agonists were selected from the literature and a maximum of 250
unique conformations were generated for each molecule (with Macromodel using the
MMFF94s force field). The pharmacophore was generated using the Catalyst software
and the resulting pharmacophore was used to screen a library of about 500k compounds
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(max. of 150 conformations per molecule, generated with Catalyst). The pharmacophore
search resulted in 22794 hits (approx. 5% of the database), which were subsequently fil-
tered based on the desired physicochemical properties. The remaining 2100 compounds
were then clustered into 420 groups, using a maximum dissimilarity clustering algorithm
and one compounds from each group was isolated, based on a Bayesian ranking model.
Finally, the 420 compounds were screened at a single concentration. Out of these, only
five compounds showed more than 50% inhibition. All five compounds were confirmed
in the full curve assay. The screening process yielded 1 compound with a𝐾𝑖 activity of
less than 100 nM [40].
Challenges in pharmacophore modeling are encountered due to the complexity of pro-
tein structures, when for example, multiple binding sites are present. Additionally, one
active site may permit several binding modes and therefore, several pharmacophores
may be fit to describe the protein-ligand binding [34].
3.1.4 Pharmacophore generators
A pharmacophoric hypothesis can be generated using either ligand - based approaches
or structure - based methods. On the first occasion, where biological activities of mul-
tiple compounds are known, a sophisticated class of computational techniques can be
used to deduce features required for biological activity and identify pharmacophores. A
drawback of these ligand - based technigues is their inability to provide detailed struc-
tural information, required to design new molecules in drug discovery. On the second
occasion, structure - based pharmacophore methodology is more reliable, as it imposes
constraints required for interaction selectivity [2]. However, structure - based methods
require comprehensive knowledge of the protein’s structure and the ligand - protein in-
teractions in the binding pocket.
There are several commercial packages that enable pharmacophore modeling, such
as the Accelrys Discovery Studio (former Catalyst), Tripo’s GASP and GALAHAD,
Ligandscout by Inte:ligand, MOE by the Chemical Computing Group and Schrödinger’s
Phase software [34].
Three pharmacophore generation protocols are provided by the Accelrys Discovery
Studio (the commercial successor of the Catalyst software); the Receptor - Ligand Phar-
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macophore Generation protocol, the Common Feature Pharmacophore Generation pro-
tocol and the 3D QSAR Pharmacophore Generation feature [7]. The commercial pro-
gram Discovery Studio has a well documented process of pharmacophore generation
and statistical analyses to give indications of the validity of the hypotheses generated.
While much of the statistical analysis is automatically generated, the interpretation of
that output as well as bias from user input can greatly affect the outcome, and therefore
interpretation of the results forms an important component of such studies. Below is a
brief summary of the pharmacophore generation features of Discovery Studio.
The Receptor - Ligand Pharmacophore Generation feature utilizes interactions be-
tween receptor-ligand complexes to generate a hypothesis. The X-ray crystal structures
of such complexes become increasingly available in online databases (e.g. PDB database
overseen by theWorldwide ProteinData Bank organization). This structured-basedmethod
generates selective pharmacophore models based on receptor-ligand interactions. To
build the pharmacophore, a set of features is identified from the binding ligand and mod-
els derived from different combinations of these features are ranked, based on measures
of sensitivity and specificity. Selectivity for the models is estimated, using a Genetic
Function Approximation (GFA) model. Descriptors for the GFA are the the number of
total features in pharmacophore models and the feature-feature distance bin values [2].
The Common Feature Pharmacophore Generation protocol utilizes the HipHop algo-
rithm. It is able to generate pharmacophore models only by identification of the common
chemical features shared by the active molecules received as input and their relative
alignment to the common feature set, without having to consider biological data [28].
The algorithm can also optionally use information from inactive ligands to place ex-
cluded volume features. HipHop identifies configurations or three-dimensional spatial
arrangements of chemical features that are common to molecules in a training set. The
configurations are identified by a pruned exhaustive search, starting with small sets of
features and extending them until no larger common configuration is found. Training
set members are evaluated on the basis of the types of chemical features they contain,
along with the ability to adopt a conformation that allows those features to be superim-
posed on a particular configurations. The user can define howmanymolecules must map
completely or partially to the pharmacophore. This option allows broader and more di-
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verse pharmacophores to be generated. The resultant pharmacophores are ranked as they
are built. The ranking is a measure of how well the molecules map onto the proposed
pharmacophores, as well as the rarity of the pharmacophore model. If a pharmacophore
model is less likely to map to an inactive compound, it will be given a higher rank; the
reverse is also true. [7]
The 3D QSAR Pharmacophore Generation feature utilizes the HypoGen algorithm to
derive Structure Activity Relationship (SAR) 3D pharmacophore models from a set of
molecules for which activity values are known (predictive pharmacophores). It consist
of a stepwise process, that receives as input data concerning ligand 3D structure and
associated biological activity. The algorithm can be modified to place excluded volumes
in key locations in an attempt to model unfavorable steric interactions.[7]
3.1.5 The HypoGen Module of Discovery Studio
When using the 3D QSAR Pharmacophore Generation feature in Discovery Studio,
the quality of the training set substantially affects the significance of the hypothesis gen-
erated. It should consist of at least 16 compounds, spanning a minimum of 4 orders
of magnitude of activity. Redundant data (i.e. compounds whose structural information
– and therefore biological activity – essentially explain the same structure/activity out-
come) should be removed as its inclusion can bias the output. The training set should
not contain compounds known to be inactive due to steric interactions with the receptor,
that is, exclusion volume problems, as DS is not equipped to handle such cases as it does
not have the capability to understand features that have a negative impact on activity. In-
clusion of these compounds would therefore lead to a bias in the pharmacophore.[29]
The 3D QSAR Pharmacophore Generation protocol carries out conformation analysis
for the input ligands, using an algorithm developed specifically to ensure good coverage
of conformational space within a minimal number of conformers. The program gener-
ates a maximum of 256 different poses for each molecule, all within a specified energy
range, and selected so that differences in inter-function distances are maximized. Chemi-
cal features from all the conformations are considered by HypoGen. A maximum of five
features obtained, and can include hydrogen bond donors, hydrogen bond acceptors, hy-
drophobic features (aliphatic and aromatic) and ionisable groups, among others. These
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chemical features are defined within Discovery Studio in a dictionary using the CHM
language and are based on atomic characteristics.[29] The in-built HypoGen module is
then able to use all this information to generate the top ten scoring hypothesis models.
This is performed in three phases [29]:
1. The constructive phase generates hypotheses that are common among the most
active compounds. This is done in several steps; first the most active compounds
are identified, then all hypotheses among the two most active compounds are de-
termined and stored, those that fit the remaining active compounds are kept.
2. The subtractive phase then removes the hypotheses that fit the inactive compounds
as well. This is performed by determining the inactive compounds, defined as
having an activity 3.5 orders of magnitude greater than the most active compound.
Any hypothesis that matched more than half the compounds identified as being
inactive is removed.
3. The final phase is the optimization phase. This involves each hypothesis undergo-
ing small perturbations in an attempt to improve the cost of the model. Examples
of some of the alterations include, rotating vectors attached to features, translat-
ing pharmacophore features, adding a new feature or removing a feature. The ten
highest scoring unique hypotheses are then exported.
These ten returned hypothesis models are analyzed to determine the best model. This
process involves a mapping analysis, as well as a thorough cost analysis (statistical anal-
ysis) to determine which hypotheses are the most likely to be an accurate representation
of the data.
The mapping analysis of HypoGen makes the assumption that an active molecule
should map more features than an inactive molecule. Therefore a molecule should be
inactive because it either does not contain an important feature, or misses the feature
as it cannot be orientated correctly in space. Based on this assumption the most active
compounds should map all features of the hypothesis model. [29]
The most accurate hypothesis model can be distinguished by plotting for each hypoth-
esis a graph of the estimated activities against the actual activities. By calculating the
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line of best fit, a correlation value is obtained for each different hypothesis, allowing for
a direct evaluation of the models performance. [29]
A major assumption used within DS in the generation of hypothesis models is based
upon Ocram’s razor, which states that between otherwise equivalent alternatives, the
simplest model is the best. Aiming to quantify the simplicity of the models, costs are
assigned to hypotheses in terms of the number of bits required to generate them. The
total hypothesis cost is calculated using the three cost factors [29]:
1. The weight cost - increases as the feature weights in a model deviate from an ideal
value
2. The error cost - increases as the RMS difference between the estimated and actual
activities for the training set molecules increases.
3. Configuration cost - a fixed cost that depends on the complexity of the hypothesis
space being optimized. Therefore, the lower the cost of a hypothesis the less bits
required to generate it and the simpler the model.
An analysis of the costs of generating the pharmacophore can also serve as a means
to validate the significance of the model. The greater the difference between the null
cost and the total cost the more statistically valid the hypothesis, and thus, the greater
the probability of this model being a true representation of the data. The null cost is
the cost of generating a hypothesis where the error cost is high. The total cost is the
actual cost of hypothesis generation, and the fixed cost is where the error cost is minimal
(perfect pharmacophore). If the difference between the total cost and the null hypothesis
cost is more than 60 bits, there is greater than 90% probability that the model is a true
representation of the data. If the difference is 40-60 bits, there is a 75-90% chance that it
represents a true correlation of the data. When the difference becomes less than 40 bits,
the probability of the hypothesis being a true representation rapidly falls below 50% and
if the total-null cost difference is less than 20 bits there is little chance of it being accurate
and the training set should be reconsidered [29].
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Figure 3.1: Serial X-ray crystallography structure of the Beta2-adrenergic receptor
P057550.[19] Complex with ligands dodecathylene glycol, acetamide, 1,4 butanediol,
(S)-carazolol, cholesterol, beta-maltose, palmitic acid, sulfate ion.
3.2 HypoGen 3D QSAR pharmacophore generation for
P07550
The P07550 protein target is a human Beta-2 adrenergic receptor, that mediates the
catecholamine-induced activation of adenylate cyclase through the action of G proteins.
The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater
affinity than it does norepinephrine [13]. The 3D structure of P07550 is presented in
figure 3.1.
The psycholeptic and psychoanaleptic drugs interacting with P07550, as well as the
plant-based food that has been found to target the same protein are listed in the following
tables 3.1 and 3.2. This data has been derived from NutriChem 1.0 and Drugbank, in a
similar process, as in chapter 2., where the comprehensive interaction networks were
constructed. It can be observed that P07550 is frequently targeted by psycholeptic and
psychoanaleptic drugs, though the pharmacological action of those interactions is yet
unclear. At the same time, nutrients contained in opium poppy and licorice also interact
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with the receptor.
Table 3.1: Psycholeptic and psychoanaleptic drug interactions for P07550
Drug interactions for P07550
Drugbank code Interaction Pharmacological action ATC Category
DB06216 Antagonist unknown Psycholeptics
DB00334 Other/Unkown unknown Psycholeptics
DB00540 Antagonist unknown Psychoanaleptics
DB01151 Antagonist unknown Psychoanaleptics
DB00182 Agonist unknown Psychoanaleptics
Table 3.2: Plant-based food interactions for P07550
Food interactions for P07550
Nutrient Food Taxonomy ID Common name
Glutamic Acid TAXID:3469 Opium poppy
Liquiritin TAXID:49827 Licorice
Wogonin TAXID:49827 Licorice
3.2.1 Methodology & Model parameters
In order to built the pharmacophore hypothesis for P07550, initially, biological activ-
ity data were extracted from the ChEMBL database [5] (accesed: October 2015). The
HypoGen algorithm cannot convert different types of activities and therefore cannot
compare the activities of molecules, if they are expressed in different reference systems
(eg. 𝐼𝐶50, 𝐾𝑖, 𝑙𝑜𝑔𝐼𝐶50, etc.). For that purpose, only compounds with known 𝐾𝑖 ac-
tivities were isolated from the bioassays of ChEMBL. The 𝐾𝑖 activity is an intrinsic,
thermodynamic quantity that is independent of the substrate (ligand) but depends on
the enzyme (target) and characterizes the thermodynamic equilibrium [9]. Lower val-
ues of𝐾𝑖 indicate higher biological activity. The ligands with know𝐾𝑖 activity against
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P07550 were converted in 3D structures using the MolConvert command line program
in Marvin 15.11.30, 2015, ChemAxon (http://www.chemaxon.com), using their canoni-
cal SMILES as input. This way, a 3D library of 484 ligands with known activities was
constructed.
The training set for HypoGen should consist of at least 16 compounds, spanning a
minimum of 4 orders of magnitude of activity. Redundant data should be removed as
its inclusion can bias the output. From the pool of 484 ligands, a subset of 50 ligands
with satisfactorily diverse properties was selected, using the Cluster Ligands protocol of
Discovery Studio. The selection was based on a maximum dissimilarity method, where
the distance function between the molecules was a Euclidean distance, because numeric
structures were used to describe the 3D structures. When a Euclidean distance is used in
the Cluster Ligands protocol of DS, each numeric property is first shifted and scaled so
that each property has a mean of 0 and standard deviation of 1. The final distance is then
scaled by the square root of the number of dimensions [7]. The 50 diversemolecules were
then minimized, using CHARMm Forcefield. Any missing hydrogens were also added
at this stage. As training set, 34 ligands from the minimized data set were selected, with
activities ranging from 0.16 to 794,328. The remaining 16 minimized ligands were used
as an external validation set. The data sets are presented in tables 3.3 and 3.4.
The HypoGen algorithm was adjusted to select maximum 5 of each one of the fol-
lowing features for 3D quantitative pharmacophore modelling; hydrogen bond acceptor
(HBA), hydrogen bond donor (HBD), hydrophobic (HY), aromatic ring (RA) and neg-
ative ionizable feature(NegIonizable). The FAST method has been applied to collect a
representative set of conformers for the training set ligands. The conformers were chosen
within a range of energetically reasonable conformations for each compound. In partic-
ular, all conformers within a range of 20 kcal/mol with respect to the global minimum,
have been employed to build the pharmacophore hypothesis. Maximum 255 conformers
were generated per structure. The uncertainty value for the activity data was set to two
(maximum uncertainty). Minimum inter-feature distance of 2.97 ̇𝐴 was set, as default.
Fischer validation index was set to 95% which was implemented together with the
establishment of HypoGen pharmacophore model. The test set of 16 molecules was
mapped to candidate hypothesis for validation by using ligand pharmacophore mapping
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protocol. The rigid fitting method was adopted for ligand pharmacophore mapping of
the validation set, allowing for each ligand to miss all but one features of the pharma-
cophore (e.g. if the pharmacophore consisted of 4 features, a ligand could miss up to 3
features).
Table 3.3: The 16 ligands used as external validation set for P07550, after the minimiza-
tion process.
Index ChEMBL ID 𝐾𝑖 Activity Uncertainty Forcefield Partial Charge Method Intitial Potential Energy Potential Energy
1 CHEMBL513389 0.631 2 CHARMm MomanyRone 25.9879 6.794
2 CHEMBL3298330 5.01 2 CHARMm MomanyRone 44.0581 -44.3315
3 CHEMBL1258599 14 2 CHARMm MomanyRone 18.8895 -27.0613
4 CHEMBL199824 60.6 2 CHARMm MomanyRone 33.7525 12.4483
5 CHEMBL1084773 110 2 CHARMm MomanyRone 61.4172 28.8918
6 CHEMBL2204360 560 2 CHARMm MomanyRone 22.9094 12.2861
7 CHEMBL1209157 1,000 2 CHARMm MomanyRone 76.8788 50.0608
8 CHEMBL25856 1,200 2 CHARMm MomanyRone 27.529 1.01987
9 CHEMBL458002 2,398.83 2 CHARMm MomanyRone 81.4903 38.2892
10 CHEMBL2068577 6,606.93 2 CHARMm MomanyRone 62.7838 -22.874
11 CHEMBL569270 10,000 2 CHARMm MomanyRone 11.886 -15.9227
12 CHEMBL2203551 10,000 2 CHARMm MomanyRone 27.8513 9.25367
13 CHEMBL1630578 15,578 2 CHARMm MomanyRone 100.449 44.7566
14 CHEMBL40317 15,800 2 CHARMm MomanyRone 18.8512 -31.4942
15 CHEMBL1622248 39,810.70 2 CHARMm MomanyRone 49.3216 20.3858
16 CHEMBL54716 100,000 2 CHARMm MomanyRone 73.3512 20.1177
3.2.2 Pharmacophore model for P07550
The HypoGen module generated successfully 10 pharmacophore hypothesis. The 4
hypothesis that were ranked as best are presented below in figure 3.2. It can be observed
that 4 hypothesis contain one hydrophobic feature and one aromatic ring, however they
vary on the number and relative position of the hydrogen bond donors.
The quality of HypoGen pharmacophore hypotheses is described by fixed cost, null
cost, total cost and some other statistical parameters. In a significant pharmacophore
model, cost difference between the null and total cost should be remarkable (>60). More-
over, higher correlation and lower RMSD are always good statistical indicators for a
model’s efficiency. [39]. These results for the 10 hypothesis can be found in table 3.5.
The first hypothesis is selected as the best available model, according to the above crite-
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Table 3.4: The 34 ligands used as training set for P07550, after the minimization process.
Index ChEMBL ID 𝐾𝑖 Activity Uncertainty Forcefield Partial Charge Method Intitial Potential Energy Potential Energy
1 CHEMBL723 0.166 2 CHARMm MomanyRone 51.7482 23.5237
2 CHEMBL499 0.201 2 CHARMm MomanyRone 42.1459 0.01061
3 CHEMBL387852 2.82 2 CHARMm MomanyRone 11.7734 -28.6112
4 CHEMBL29141 5 2 CHARMm MomanyRone 54.4131 7.67004
5 CHEMBL1800934 12.71 2 CHARMm MomanyRone 46.9807 -1.23621
6 CHEMBL357995 14 2 CHARMm MomanyRone 18.0999 -17.2776
7 CHEMBL249359 38 2 CHARMm MomanyRone 29.2774 -64.4839
8 CHEMBL250352 49 2 CHARMm MomanyRone 36.5459 10.8418
9 CHEMBL1683936 61 2 CHARMm MomanyRone 37.9087 -15.2891
10 CHEMBL1221801 151 2 CHARMm MomanyRone 25.605 -7.0682
11 CHEMBL188622 223 2 CHARMm MomanyRone 137.603 -7.40492
12 CHEMBL462313 320 2 CHARMm MomanyRone 34.366 9.55272
13 CHEMBL497963 501.19 2 CHARMm MomanyRone 68.538 -0.23249
14 CHEMBL281350 1,000 2 CHARMm MomanyRone 118.903 71.7545
15 CHEMBL1098230 1,000 2 CHARMm MomanyRone 6.99728 -4.25591
16 CHEMBL1242950 1,000 2 CHARMm MomanyRone 37.6626 21.8012
17 CHEMBL1242923 1,000 2 CHARMm MomanyRone 46.6601 24.9096
18 CHEMBL707 1,889 2 CHARMm MomanyRone 45.4829 19.3003
19 CHEMBL442 1,898 2 CHARMm MomanyRone 75.696 8.32702
20 CHEMBL787 2,398 2 CHARMm MomanyRone 58.8235 -5.4701
21 CHEMBL40650 3,870 2 CHARMm MomanyRone 28.4613 0.82565
22 CHEMBL565547 7,600 2 CHARMm MomanyRone 16.364 -0.83703
23 CHEMBL229429 10,000 2 CHARMm MomanyRone 35.8521 3.77239
24 CHEMBL3104093 10,000 2 CHARMm MomanyRone 52.2738 42.2754
25 CHEMBL6310 10,000 2 CHARMm MomanyRone 23.9959 10.6719
26 CHEMBL30713 10,000 2 CHARMm MomanyRone 12.5588 -0.19888
27 CHEMBL555146 10,000 2 CHARMm MomanyRone 50.7249 32.049
28 CHEMBL495075 10,000 2 CHARMm MomanyRone 49.2167 21.5371
29 CHEMBL1824265 10,000 2 CHARMm MomanyRone 27.0155 -17.8479
30 CHEMBL72168 13,900 2 CHARMm MomanyRone 18.2649 -25.8226
31 CHEMBL2070835 25,118.90 2 CHARMm MomanyRone 29.6519 7.93831
32 CHEMBL57163 100,000 2 CHARMm MomanyRone 27.3846 4.78856
33 CHEMBL226292 100,000 2 CHARMm MomanyRone 28.8216 -47.4604
34 CHEMBL1626178 794,328 2 CHARMm MomanyRone 40.8516 20.3985
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Figure 3.2: The four best pharmacophore hypothesis generated for P07550. The features
depicted include the aromatic ring (orange), hydrophobic (light blue) and hydrogen bond
donor (purple). It can be observed that 4 hypothesis contain one hydrophobic feature and
one aromatic ring, however they vary on the number and relative position of the hydrogen
bond donors.
ria. This hypothesis is depicted in figure 3.3.
The mappings of training set compounds and the correlation between their actual and
predicted biological activities are elucidated in the plot of figure 3.4, where a line of best
fit has been drawn for the two variables.
3.2.3 Model validation & Interpretation of results
The model of hypothesis 1 for protein P07550 was validated in three ways. First, a
Fisher’s test with a significance of 95% was implemented during the generation of the
model. At the same time, the model was tested against the external validation test of
table 3.3. Finally, an additional validation method was applied with a database of 484
compounds, with varied activities against the target, to further assess the ability of the
model to differentiate between active and inactive ligands.
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Figure 3.3: The first phamacophore hypothesis, which was selected as best available
model for P07550. (a) Coordinates of the features. (b) Mapping of the most active com-
pound CHEMBL723 with𝐾𝑖 = 0.166(c) 2D structure of CHEMBL723.
Table 3.5: Results of ten top scored pharmacophore hypotheses generated by HypoGen.
(P07550)
Hypothesis Total cost Cost difference RMSD Correlation coefficient Features
1 234.504 312.062 2.59087 0.863333 HBD HBD HY RA
2 256.817 289.749 2.65633 0.857371 HBD HY RA
3 266.236 280.33 2.91343 0.823481 HBD HBD HY RA
4 273.068 273.498 3.00371 0.810945 HBD HBD HY RA
5 275.592 270.974 2.78957 0.842347 HBD HY RA
6 282.446 264.12 3.1036 0.796494 HBD HBD HY RA
7 285.612 260.954 3.12473 0.793396 HBD HBD HY RA
8 286.518 260.048 2.95411 0.819972 HBD HY RA
9 287.087 259.479 3.0772 0.800937 HBD HY RA
10 287.367 259.199 3.14223 0.790763 HBD HBD HY RA
Note: Cost difference is the difference between null and total cost; null cost is 546.566; fixed cost is 287.087.
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Figure 3.4: Correlation and line of best fit for estimated activity vs actual activity of
training set for hypothesis 1 (P07550).
In the first validation method, a Fisher’s randomization test was carried out by Dis-
covery Studio. The null hypothesis was that the actual 𝐴𝑟𝑒𝑎𝑙 and predicted 𝐴𝑝𝑟𝑒𝑑𝑖𝑐𝑡 ac-
tivities for the ligands against the target were unrelated variables. A randomization test
was carried out, instead of Fisher’s exact test, since the sample size causes the number of
possible combinations to increase dramatically, to the point where a computer may have
a hard time doing all the calculations in a reasonable period of time. The randomization
test works by generating random combinations of numbers in the𝐴𝑟𝑒𝑎𝑙×𝐴𝑝𝑟𝑒𝑑𝑖𝑐𝑡 table,
with the probability of generating a particular combination equal to its probability under
the null hypothesis. For each combination, the Pearson’s chi-square statistic is calculated.
The proportion of these random combinations that have a chi-square statistic equal to or
greater than the observed data is the P-value. For a significance of 95%, if the P-value
is smaller or equal than 0.05, there is strong evidence against the null hypothesis. There-
fore, the predicted activity is strongly correlated to the actual activity. If the P-value is
bigger than 0.05, there isn’t enough evidence to reject the null hypothesis [30]. In the
present statistical problem, it was found that the hypothesis 1., indeed, represented a
valid correlation, with a 95% significance.
Against the initial validation set of 16 compounds, the model of the first hypothesis
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yielded a correlation coefficient of 0.529, an RMSD of 2.463. The behavior of the model
against the external validation set is anticipated to be poorer, compared to that of the
training set, because the external test set possibly contains structural formations that
are very different from the ones used to generate the model. However, this could also
potentially indicate an over-fitting of the data.
In the next validation step, the database of 484 compounds was minimized, using
CHARMm forcefield. Then, the Build Database feature of Discovery Studio was ap-
plied, in order to generate a database, automatically indexed with sub-structure, phar-
macophore feature, and shape information to allow fast database searching. For each
compound, maximum 255 conformations were generated. The full database is presented
as supplementary material (S1). The range of activities for these compounds was be-
tween 0.1-1,160,000. The model of hypothesis 1. was selected to screen this database,
using the FAST search method, to identify active candidates. By choosing a cut-off at
𝐾𝑖 = 1, 000 (as indicated by Discovery Studio), the ligands were characterized as ac-
tive or inactive against the target. This permitted the construction of a confusion matrix,
in order to evaluate the accuracy, precision and recall of the model. This matrix can be
found in table 3.6.
Table 3.6: Confusion (or contingency) table for pharmacophore hypothesis 1 (P07550).
Database of 484 compounds of activities ranging between 0.1-1,160,000. Cut-off
method at𝐾𝑖 = 1, 000.
Predicted Active Predicted Inactive Total
Active 137 192 329
Inactive 46 109 155
Total 183 301 484
The confusion matrix records the number of compounds that were predicted active
and were actually active (true positives, TP), the number predicted inactive but actually
active (false negatives, FN), the number predicted active but actually negative (false
negatives, FN) and predicted inactive and actually inactive (true negatives, TN). While
evaluating the confusion matrix the following statistical indices are taken into account
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[43]:
1. Accuracy, or the proportion of the total number of predictions that were correct:
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 𝑇𝑁 + 𝑇𝑃𝑇𝑁 + 𝑇𝑃 + 𝐹𝑁 + 𝐹𝑃 (3.1)
2. Precision, or the fraction of the compounds returned as active which are active:
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 𝑇𝑃𝑇𝑃 + 𝐹𝑃 (3.2)
3. Recall, or the fraction of actives which are actually identified. Coincides with
TP%.
𝑅𝑒𝑐𝑎𝑙𝑙 = 𝑇𝑃𝑇𝑃 + 𝐹𝑁 (3.3)
4. f-score, the harmonic mean of precision and recall:
𝑓 = 2𝑇𝑃2𝑇𝑃 + 𝐹𝑃 + 𝐹𝑁 (3.4)
The accuracy of the hypothesis was 50.8% and its precision was found to be 74.9%.
Moreover, the true positive recall was specified as 41.6% and the f-score was 53.5%.
These results show that, even though the model is not as accurate in distinguishing active
from inactive ligands, as desired, and a lot of the actives were missed, it has very good
precision. Therefore, positive predictions are almost always actual active compounds.
3.3 HypoGen 3D QSAR pharmacophore generation for
P28222
P28882 or 5-HT1B-BRIL is a G-protein coupled receptor for 5-hydroxytryptamine
(serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic
and antidepressant drugs and other psychoactive substances, such as lysergic acid diethy-
lamide (LSD). Ligand binding causes a conformation change that triggers signaling via
guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-
stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
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Figure 3.5: Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with
dihydroergotamine (PSI Community Target).[38]
Arrestin family members inhibit signaling via G proteins and mediate activation of al-
ternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine
and acetylcholine in the brain, and thereby affects neural activity, nociceptive process-
ing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of
cerebral arteries [13]. The 3D structure of P28222 is presented in figure 3.5. Ligands are
usually bound in a hydrophobic pocket formed by the transmembrane helices [13].
The psycholeptic and psychoanaleptic drugs interacting with P28222, as well as the
plant-based food that has been found to target the same protein are listed in the following
tables 3.7 and 3.8. It can be observed that several psycholeptics and psychoanaleptics
bind or act as antagonists to the receptor. Furthermore, interactions with plant-based food
are anticipated for ginger, potatoes, safflower and tomato, that contain serotonin.
3.3.1 Methodology & Model parameters
In order to built the pharmacophore hypothesis for P28222, biological activity data
were extracted from the ChEMBL database [5] (accesed: October 2015) and processed
in the same way, as for P07550. The ligands with know 𝐾𝑖 activity against P28222
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Table 3.7: Psycholeptic and psychoanaleptic drug interactions for P28222
Drug interactions for P28222
Drugbank code Interaction Pharmacological action ATC Category
DB01224 OtherUnkown unknown Psycholeptics
DB00408 Binder unknown Psycholeptics
DB00363 Antagonist unknown Psycholeptics
DB00246 Antagonist unknown Psycholeptics
DB01238 Antagonist unknown Psycholeptics
DB00543 Antagonist unknown Psychoanaleptics
DB00321 Binder unknown Psychoanaleptics
Table 3.8: Plant-based food interactions for P28222
Food interactions for P28222
Nutrient Food Taxonomy ID Common name
Serotonin TAXID:94328 Ginger
Serotonin TAXID:4222 Safflower
Serotonin TAXID:4081 Tomato
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were converted in 3D structures using theMolConvert command line program inMarvin
15.11.30, 2015, ChemAxon (http://www.chemaxon.com), using their canonical SMILES
as input. This way, a 3D library of 901 ligands with known activities was constructed.
From this library, a subset of 49 ligands with satisfactorily diverse properties was se-
lected, using the Cluster Ligands protocol of Discovery Studio, as before. The 49 diverse
molecules were then minimized, using CHARMm Forcefield. Any missing hydrogens
were also added at this stage. As training set, 34 ligands from the minimized data set
were selected, with activities ranging from 0.96 to 10,000. The remaining 15 minimized
ligands were used as an external validation set. The two data sets are presented in tables
3.10 and 3.9.
The parameters specified for the HypoGen algorithm were the same as for protein
P07550. The algorith was adjusted to select maximum 5 of each one of the following
features for 3D quantitative pharmacophore modelling; hydrogen bond acceptor (HBA),
hydrogen bond donor (HBD), hydrophobic (HY), aromatic ring (RA) and negative ion-
izable feature(NegIonizable). The FAST method has been applied to collect a represen-
tative set of conformers for the training set ligands. The conformers were chosen within
a range of energetically reasonable conformations for each compound. In particular, all
conformers within a range of 20 kcal/mol with respect to the global minimum, have been
employed to build the pharmacophore hypothesis. Maximum 255 conformers were gen-
erated per structure. The uncertainty value for the activity data was set to two (maximum
uncertainty). Minimum inter-feature distance of 2.97 ̇𝐴 was set, as default.
Fisher validation index was, again, set to 95% which was implemented together with
the establishment of HypoGen pharmacophore model. The test set of 15 molecules was
mapped to candidate hypothesis for validation, and the rigid fitting method was adopted
for ligand pharmacophore mapping of the validation set, allowing for each ligand to miss
all but one features of the pharmacophore.
3.3.2 Pharmacophore model for P28222
The HypoGen module generated successfully 10 pharmacophore hypothesis. The 4
hypothesis that were ranked as best are presented below in figure 3.6. It can be observed
that the two first hypothesis contain two hydrophobic features, one aromatic ring, and
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Table 3.9: The 34 ligands used as training set for P28222, after the minimization process.
Index ChEMBL ID Ki Activity Uncertainty Forcefield Partial Charge Method Intitial Potential Energy Potential Energy
1 CHEMBL601013 0.96 2 CHARMm MomanyRone 56.6094 24.4612
2 CHEMBL442 2.1 2 CHARMm MomanyRone 75.696 8.32702
3 CHEMBL198488 3.98 2 CHARMm MomanyRone 118.423 70.0094
4 CHEMBL85 10 2 CHARMm MomanyRone 59.507 27.2564
5 CHEMBL355517 32 2 CHARMm MomanyRone 26.105 5.94079
6 CHEMBL319352 48 2 CHARMm MomanyRone 52.83 14.0227
7 CHEMBL104374 110 2 CHARMm MomanyRone 25.8071 7.89435
8 CHEMBL107772 150 2 CHARMm MomanyRone 9.46981 -60.0958
9 CHEMBL425190 199.53 2 CHARMm MomanyRone 61.1205 49.039
10 CHEMBL393169 300 2 CHARMm MomanyRone 52.0014 25.9022
11 CHEMBL2413153 411 2 CHARMm MomanyRone 37.6139 8.06594
12 CHEMBL244946 501.19 2 CHARMm MomanyRone 73.3816 38.928
13 CHEMBL2424668 700 2 CHARMm MomanyRone 46.484 17.5512
14 CHEMBL203013 720 2 CHARMm MomanyRone 50.2642 30.9616
15 CHEMBL458002 776.25 2 CHARMm MomanyRone 81.4903 38.2892
16 CHEMBL38465 1,000 2 CHARMm MomanyRone 16.1349 0.16076
17 CHEMBL715 1,000 2 CHARMm MomanyRone 63.0408 38.3711
18 CHEMBL1242950 1,000 2 CHARMm MomanyRone 37.6626 21.8012
19 CHEMBL339980 1,060 2 CHARMm MomanyRone 30.3097 4.65631
20 CHEMBL139230 1,120 2 CHARMm MomanyRone 23.2803 10.1596
21 CHEMBL360803 1,980 2 CHARMm MomanyRone 23.3446 7.12036
22 CHEMBL71676 2,024 2 CHARMm MomanyRone 16.2114 3.57228
23 CHEMBL229429 10,000 2 CHARMm MomanyRone 35.8521 3.77239
24 CHEMBL1794855 10,000 2 CHARMm MomanyRone -2.01882 -101.981
25 CHEMBL1258843 10,000 2 CHARMm MomanyRone -8.30133 -35.1111
26 CHEMBL70988 10,000 2 CHARMm MomanyRone 24.3354 12.8505
27 CHEMBL338115 10,000 2 CHARMm MomanyRone 16.9741 -2.65065
28 CHEMBL71751 10,000 2 CHARMm MomanyRone 50.2933 20.719
29 CHEMBL139976 10,000 2 CHARMm MomanyRone 14.4727 7.74292
30 CHEMBL1189234 10,000 2 CHARMm MomanyRone 78.1977 66.6188
31 CHEMBL371300 10,000 2 CHARMm MomanyRone 22.6007 -0.26914
32 CHEMBL2058429 10,000 2 CHARMm MomanyRone 69.2834 36.5829
33 CHEMBL2181187 10,000 2 CHARMm MomanyRone 42.1677 26.7867
34 CHEMBL2031737 10,000 2 CHARMm MomanyRone 83.4966 48.9074
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Table 3.10: The 15 ligands used as external validation set for P28222, after the minimiza-
tion process.
Index ChEMBL ID Ki Activity Uncertainty Forcefield Partial Charge Method Intitial Potential Energy Potential Energy
1 CHEMBL370110 2.5 2 CHARMm MomanyRone 91.8835 68.501
2 CHEMBL15933 31.62 2 CHARMm MomanyRone 73.9576 38.6059
3 CHEMBL2204360 33 2 CHARMm MomanyRone 22.9094 12.2861
4 CHEMBL467094 100 2 CHARMm MomanyRone 78.7629 52.0283
5 CHEMBL126340 190 2 CHARMm MomanyRone 94.6274 19.3007
6 CHEMBL3217984 316.23 2 CHARMm MomanyRone 65.0853 51.6073
7 CHEMBL73281 600 2 CHARMm MomanyRone 23.1011 -4.66025
8 CHEMBL2260930 751.8 2 CHARMm MomanyRone 55.1366 -2.35408
9 CHEMBL311694 1000 2 CHARMm MomanyRone 65.3363 24.5109
10 CHEMBL233212 1000 2 CHARMm MomanyRone 86.9175 48.1739
11 CHEMBL376344 1000 2 CHARMm MomanyRone 30.4082 -8.39994
12 CHEMBL3104091 1348.96 2 CHARMm MomanyRone 42.5095 31.5714
13 CHEMBL1642866 5000 2 CHARMm MomanyRone 139.27 63.6545
14 CHEMBL269538 10000 2 CHARMm MomanyRone 22.3699 6.8177
15 CHEMBL569270 10000 2 CHARMm MomanyRone 11.886 -15.9227
one hydrogen bond donor. However, the positions and orientations of the features vary.
The third and fourth pharmacophores are slightly differentiated, as they feature three
hydrophobic groups, instead of two. The statistical results (null cost, total cost, RMSD
and correlation coefficient) for the 10 hypothesis can be found in table 3.11. The first
hypothesis is selected as the best available model, according to the above criteria. This
hypothesis is depicted in figure 3.7.
The mappings of training set compounds and the correlation between their actual and
predicted biological activities are depicted in figure 3.8.
3.3.3 Model validation & Interpretation of results
Themodel of hypothesis 1 for protein P28222 was validated in three ways, similarly to
P07550. A Fisher’s test with a significance of 95% was implemented during the genera-
tion of the model, and an external data test, presented in table 3.10, was used as external
validation. Finally, the model was used to screen a database of 200 compounds, with var-
ied activities against the target, to further assess the ability of the model to differentiate
between active and inactive ligands.
During the validation with Fisher’s randomization test, the null hypothesis stated that
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Figure 3.6: The four best pharmacophore hypothesis generated for P28222. The features
depicted include the aromatic ring (orange), hydrophobic (light blue) and hydrogen bond
donor (purple).
Table 3.11: Results of ten top scored pharmacophore hypotheses generated by Hy-
poGen.(P28222)
Hypothesis Total cost Cost difference RMSD Correlation coefficient Features
1 198.883 144.26 2.1958 0.815277 HBD HY HY RA
2 210.691 132.45 2.34836 0.785151 HBD HY HY RA
3 223.601 119.54 2.49353 0.75344 HBD HY HY HY RA
4 225.307 117.83 2.51288 0.748959 HBD HY HY HY RA
5 233.839 109.3 2.61343 0.724623 HBA HBD HY RA
6 235.464 107.68 2.64042 0.717728 HBA HBD HY RA
7 237.056 106.09 2.65639 0.713633 HBA HY RA
8 238.146 105 2.65935 0.712923 HBA HBD HY RA
9 241.958 101.18 2.70405 0.701117 HBA HBD HY RA
10 243.51 99.631 2.7158 0.697981 HBD HY HY HY RA
Note: Cost difference is the difference between null and total cost; null cost is 343.141; fixed cost is 116.911.
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Figure 3.7: The first phamacophore hypothesis, which was selected as best available
model for P28222. (a) Coordinates of the features. (b) Mapping of the most active com-
pound CHEMBL601013 with𝐾𝑖 = 0.96. (c) 2D structure of CHEMBL601013.
Figure 3.8: Correlation and line of best fit for estimated activity vs actual activity of
training set for hypothesis 1 (P28222).
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no correlation exists between the actual and predicted activities of the ligands against the
P28222. In the present statistical problem, it was found that the P-value for hypothesis 1.
was smaller or equal than 0.05, and therefore there was strong evidence against the null
hypothesis. A valid correlation between actual and predicted activities was established
with 95% significance.
Against the initial validation set of 15 compounds, the model of the first hypothesis
yielded a correlation coefficient of 0.478, an RMSD of 1.852. The behavior of the model
against the external validation set is very poor, because the external test set possibly
contains structural formations that are very different from the ones used to generate the
model. However, this could also potentially indicate an over-fitting of the data.
In the next validation step, the Build Database feature of Discovery Studio was applied
to the data set of 200 compounds, in order to generate a database, automatically indexed
with sub-structure, pharmacophore feature, and shape information to allow fast database
searching. For each compound, maximum 255 conformations were generated. The full
database is presented as supplementary material (S2). The range of activities for these
compounds was between 0.14-30,000. The model of hypothesis 1. was selected to screen
this database, using the FAST searchmethod, to identify active candidates. By choosing a
cut-off at𝐾𝑖 = 6, 000 (as indicated byDiscovery Studio), the ligands were characterized
as active or inactive against the target. This permitted the construction of a confusion
matrix, in order to evaluate the accuracy, precision and recall of the model. This matrix
can be found in table 3.12.
Table 3.12: Confusion (or contingency) table for pharmacophore hypothesis 1 (P28222).
Database of 200 compounds of activities ranging between 0.14-30,000. Cut-off method
at𝐾𝑖 = 6000.
Predicted Active Predicted Inactive Total
Active 18 147 165
Inactive 1 34 35
Total 19 181 200
From the confusion table, it becomes apparent that the accuracy of the prediction is
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Figure 3.9: Neuronal calcium sensor-1 (NCS-1)from Rattus norvegicus complex with
D2 dopamine receptor peptide from Homo sapiens [35]. Calcium and potassium ions
are bound as co-factors in the complex.
26.0%, the precision 94.7%, the recall only 10.9% and the f-score 19.6%. This hypothesis
is very precise in identifying true actives, however it appears to have a very high false
negative rate (low recall). Therefore, a lot of actives in the data set were missed, because
the restrictions imposed by the model were too specific. This could indicate an over-
fitting of the model on the training set, or could be attributed to different binding modes
of ligands present on the data set, that were not incorporated in the initial hypothesis.
3.4 HypoGen 3D QSAR pharmacophore generation for
P14416
The D(2) dopamine receptor or P14416 is a dopamine receptor whose activity is me-
diated by G proteins which inhibit adenylyl cyclase [13]. The 3D structure for P14416
is presented in figure 3.9.
The psycholeptic and psychoanaleptic drugs interacting with P14416, as well as the
plant-based food that has been found to target the same protein are listed in the following
tables 3.13 and 3.14. This data has been derived from NutriChem 1.0 and Drugbank,
in a similar process, as in chapter 2., where the comprehensive interaction networks
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were constructed. It is noted that P14416 is registered as a very common target for both
psycholeptics and psychoanaleptics, whose pharmacological action as antagonists of the
dopamine receptor is well established. However, several nutrients seem to interact with
the same target; banana, barley, garlic, garden pea, cacao and opium poppy are all cited
as plant-based food that contains phytochemicals, active against P14416.
3.4.1 Methodology & Model parameters
In order to built the pharmacophore hypothesis for P14416, biological activity data
were extracted from the ChEMBL database [5] and processed in the same way, as for the
two previous targest. The ligands with know𝐾𝑖 activity against P14416 were converted
in 3D structures, using their canonical SMILES as input. This way, a 3D library of 5650
ligands with known activities was constructed. From this library, a subset of 32 ligands
with satisfactorily diverse properties was selected, using the Cluster Ligands protocol
of Discovery Studio, as before. The 32 diverse molecules were then minimized, using
CHARMm Forcefield. Any missing hydrogens were also added at this stage. As training
set, 20 ligands from the minimized data set were selected, with activities ranging from
0.05 to 14,000. The remaining 12 minimized ligands were used as an external validation
set. The two data sets are presented in tables 3.16 and 3.15.
The parameters specified for the HypoGen algorithm were the same as for protein
P07550 and P28222. The algorith was adjusted to select maximum 5 of each one of the
following features for 3D quantitative pharmacophore modelling; hydrogen bond accep-
tor (HBA), hydrogen bond donor (HBD), hydrophobic (HY), aromatic ring (RA) and
negative ionizable feature(NegIonizable). The FAST method has been applied to col-
lect a representative set of conformers for the training set ligands. The conformers were
chosen within a range of energetically reasonable conformations for each compound.
In particular, all conformers within a range of 20 kcal/mol with respect to the global
minimum, have been employed to build the pharmacophore hypothesis. Maximum 255
conformers were generated per structure. The uncertainty value for the activity data was
set to two (maximum uncertainty). Minimum inter-feature distance of 2.97 ̇𝐴 was set, as
default.
Once more, Fisher validation index was set to 95% which was implemented together
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Table 3.13: Psycholeptic and psychoanaleptic drug interactions for P14416
Drug interactions for P14416
Drugbank code Interaction Pharmacological action ATC Category
DB00391 Antagonist yes Psycholeptics
DB00409 Antagonist yes Psycholeptics
DB06288 Antagonist yes Psycholeptics
DB00450 Antagonist yes Psycholeptics
DB00502 Antagonist yes Psycholeptics
DB01224 Antagonist yes Psycholeptics
DB00408 Antagonist yes Psycholeptics
DB06216 Antagonist yes Psycholeptics
DB00363 Antagonist yes Psycholeptics
DB04842 Antagonist yes Psycholeptics
DB01618 Antagonist yes Psycholeptics
DB08815 Antagonist yes Psycholeptics
DB06144 Antagonist yes Psycholeptics
DB00246 Antagonist yes Psycholeptics
DB01238 Antagonist, Partial agonist yes Psycholeptics
DB01267 Antagonist yes Psycholeptics
DB00734 Antagonist yes Psycholeptics
DB01614 Antagonist yes Psycholeptics
DB00420 Antagonist yes Psycholeptics
DB01403 Antagonist yes Psycholeptics
DB00508 Antagonist yes Psycholeptics
DB01622 Antagonist yes Psycholeptics
DB00850 Antagonist yes Psycholeptics
DB01063 Antagonist yes Psycholeptics
DB00623 Antagonist yes Psycholeptics
DB00831 Antagonist yes Psycholeptics
DB01621 Antagonist yes Psycholeptics
DB01624 Antagonist yes Psycholeptics
DB01239 Antagonist yes Psycholeptics
DB01043 Agonist unknown Psychoanaleptics
DB00543 Antagonist unknown Psychoanaleptics
DB00726 OtherUnknown unknown Psychoanaleptics
DB00458 Binder unknown Psychoanaleptics
DB01142 Antagonist unknown Psychoanaleptics
DB01151 Binder unknown Psychoanaleptics
DB00805 Agonist unknown Psychoanaleptics
DB00370 Binder unknown Psychoanaleptics
DB00182 Binder unknown Psychoanaleptics
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Table 3.14: Plant-based food interactions for P14416
Food interactions for P14416
Nutrient Food Taxonomy ID Common name
Salsolinol TAXID:89151 Banana
Tyramine TAXID:4513 Barley
Tyramine TAXID:3888 Garden pea
Trifluoperazine TAXID:4682 Garlic
Higenamine TAXID:3469 Opium poppy
Aporphine TAXID:3469 Opium poppy
Salsolinol TAXID:3641 Theobroma cacao
with the establishment of HypoGen pharmacophore model. The test set of 12 molecules
was mapped to candidate hypothesis for validation, and the rigid fitting method was
adopted for ligand pharmacophore mapping of the validation set, allowing for each lig-
and to miss all but one features of the pharmacophore.
The mappings of training set compounds and the correlation between their actual and
predicted biological activities are depicted in figure 3.10.
3.4.2 Pharmacophore model for P14416
TheHypoGenmodule generated successfully 10 pharmacophore hypothesis. The 4 hy-
pothesis that were ranked as best are presented below in figure 3.11. Hypothesis one, two
and three are comprised of hydrogen bond acceptors and donors, all with different spa-
tial arrangements. However, hypothesis three, includes one hydrophobic feature, three
hydrogen bond acceptors and does not support the existence of hydrogen bond donnors.
The statistical results (null cost, total cost, RMSD and correlation coefficient) for the
10 hypothesis can be found in table 3.17. The first hypothesis is selected as the best
available model, according to the above criteria. This hypothesis is presented in figure
3.12.
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Table 3.15: The 20 ligands used as training set for P14416, after the minimization pro-
cess.
Index ChEMBL ID Ki Activity Uncertainty Forcefield Partial Charge Method Intitial Potential Energy Potential Energy
17 CHEMBL156651 0.05 2 CHARMm MomanyRone 34.186 9.04991
20 CHEMBL1259129 1.9 2 CHARMm MomanyRone 78.1434 54.8565
19 CHEMBL147159 2.2 2 CHARMm MomanyRone 60.4403 27.9359
18 CHEMBL3265321 5.98 2 CHARMm MomanyRone 55.5861 -252.07
16 CHEMBL1087817 6.3 2 CHARMm MomanyRone 72.1295 42.4538
15 CHEMBL301265 21 2 CHARMm MomanyRone 18.7794 -4.28568
14 CHEMBL3220214 32.36 2 CHARMm MomanyRone 31.662 15.6717
13 CHEMBL3265323 64.16 2 CHARMm MomanyRone -125.768 -992.896
12 CHEMBL440512 119 2 CHARMm MomanyRone 69.9521 39.778
11 CHEMBL1223598 316.23 2 CHARMm MomanyRone 96.3959 33.1814
10 CHEMBL158973 330 2 CHARMm MomanyRone 11.6849 6.99085
9 CHEMBL99208 402 2 CHARMm MomanyRone 35.9677 13.0951
8 CHEMBL1258035 501.19 2 CHARMm MomanyRone 78.1303 45.8024
7 CHEMBL2325934 830 2 CHARMm MomanyRone 47.713 17.1369
6 CHEMBL269396 1,400 2 CHARMm MomanyRone 21.115 6.66341
5 CHEMBL40284 1,600 2 CHARMm MomanyRone 41.4219 24.7036
4 CHEMBL2205831 2,830 2 CHARMm MomanyRone 85.0433 73.5694
3 CHEMBL484203 4,100 2 CHARMm MomanyRone 65.7878 26.3962
2 CHEMBL19331 9,400 2 CHARMm MomanyRone 19.365 8.20034
1 CHEMBL241101 14,000 2 CHARMm MomanyRone 47.7179 11.492
Table 3.16: The 12 ligands used as external validation set for P14416, after the minimiza-
tion process.
Index ChEMBL ID Ki Activity Uncertainty Forcefield Partial Charge Method Intitial Potential Energy Potential Energy
1 CHEMBL2062848 12,000 2 CHARMm MomanyRone 39.8627 22.8099
2 CHEMBL141343 5,587 2 CHARMm MomanyRone 10.8383 -30.3153
3 CHEMBL165381 2,400 2 CHARMm MomanyRone -23.7392 -40.7116
4 CHEMBL211026 1,500 2 CHARMm MomanyRone 58.8052 25.8356
5 CHEMBL92939 984 2 CHARMm MomanyRone 51.4646 33.1222
6 CHEMBL21731 665 2 CHARMm MomanyRone 34.0352 25.6469
7 CHEMBL348285 355 2 CHARMm MomanyRone 24.6282 15.361
8 CHEMBL1909065 234 2 CHARMm MomanyRone 172.403 59.1701
9 CHEMBL3216146 79 2 CHARMm MomanyRone 65.8214 19.9372
10 CHEMBL3084517 40.1 2 CHARMm MomanyRone 173.425 65.5998
11 CHEMBL3234537 23 2 CHARMm MomanyRone 82.7016 20.506
12 CHEMBL1087744 2.5 2 CHARMm MomanyRone 53.5237 23.202
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Figure 3.10: Correlation and line of best fit for estimated activity vs actual activity of
training set for hypothesis 1 (P14416).
Figure 3.11: The four best pharmacophore hypothesis generated for P14416. The features
depicted include the hydrogen bond acceptor (green), the hydrophobic (light blue) and
hydrogen bond donor (purple).
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Table 3.17: Results of ten top scored pharmacophore hypotheses generated by HypoGen.
(P14416)
Hypothesis Total cost Cost difference RMSD Correlation coefficient Features
1 165.107 103.68 3.07381 0.742764 HBA HBA HBD
2 165.668 103.12 3.08537 0.740472 HBA HBA HBD
3 167.308 101.48 3.10949 0.735683 HBA HBA HBA HY
4 168.12 100.67 3.11668 0.734272 HBA HBA HBD
5 169.647 99.145 3.14744 0.727983 HBA HBA HBA HY
6 172.734 96.058 3.18791 0.719626 HBA HBA HBD
7 175.173 93.619 3.2266 0.711394 HBA HBA HBD
8 175.292 93.5 3.23369 0.709834 HBA HBA HBA HY
9 176.173 92.619 3.23918 0.708692 HBA HBA HBD
10 177.909 90.883 3.27765 0.700175 HBA HBA HBA HY
Note: Cost difference is the difference between null and total cost; null cost is 268.792; fixed cost is 70.2819.
Figure 3.12: The first phamacophore hypothesis, which was selected as best available
model for P14416. (a) Coordinates of the features. (b) Mapping of the most active com-
pound CHEMBL156651 with𝐾𝑖 = 0.05. (c) 2D structure of CHEMBL156651.
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3.4.3 Model validation & Interpretation of results
During the validation with Fisher’s randomization test, the null hypothesis stated that
no correlation exists between the actual and predicted activities of the ligands against the
P14416. It was found that the P-value for hypothesis 1. was smaller or equal than 0.35,
and therefore the null hypothesis could be rejected with a significance of 65%. Therefore,
we can assume that there is a weak correlation between actual and predicted activities.
Against the initial validation set of 12 compounds, the model of the first hypothesis
yielded a correlation coefficient of 0.278, an RMSD of 2.201. The behavior of the model
against the external validation set is very poor, because the external test set possibly
contains structural formations that are very different from the ones used to generate the
model. However, this could also potentially indicate an over-fitting of the data.
In the next validation step, the Build Database feature of Discovery Studio was ap-
plied to the data set of 199 compounds, in order to generate a database, automatically
indexed with sub-structure, pharmacophore feature, and shape information to allow fast
database searching. For each compound, maximum 255 conformations were generated.
The full database is presented as supplementary material (S3). The range of activities for
these compounds was between 0.031-88,000. The model of hypothesis 1. was selected
to screen this database, using the FAST search method, to identify active candidates. By
choosing a cut-off at 𝐾𝑖 = 300 (as indicated by Discovery Studio), the ligands were
characterized as active or inactive against the target. This permitted the construction of
a confusion matrix, in order to evaluate the accuracy, precision and recall of the model.
This matrix can be found in table 3.18.
Table 3.18: Confusion (or contingency) table for pharmacophore hypothesis 1 (P14416).
Database of 199 compounds of activities ranging between 0.031-88,000. Cut-off method
at𝐾𝑖 = 300.
Predicted Active Predicted Inactive Total
Active 15 74 89
Inactive 14 96 110
Total 29 170 199
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The accuracy, as calculated from the contingency table, is 55.8%, the recall is 16.9%,
while the precision and f-score are, respectively, 51.7% and 25.4%. The performance
of the model in distinguishing active from inactive compounds is overall mediocre. The
low recall might also be an indicator of a bias towards predicting inactive compounds,
which is not always a desirable characteristic, especially during the early stages of lead
discovery for new active compounds.
3.5 ScreeningNutriChem1.0Database to identify poten-
tially active phytochemicals
In the next part of this study, the pharmacophore models constructed for the three pro-
teins, were used to screen the database of phytochemicals that were stored in NutriChem
1.0. Through this process, additional nutrients, that are constituents of plant-based food,
could be identified as potentially active for the three targets of psychiatric drugs.
3.5.1 Building a 3D conformation database for NutriChem 1.0
The database of phyrotchemicals in NutriChem was available in the form of canoni-
cal SMILES, that had to be converted into 3D structures. This process was carried out
using the MolConvert command line program in Marvin 15.11.30, 2015, ChemAxon
(http://www.chemaxon.com). The molecules were then minimized, using CHARMm
Forcefield, and the minimization feature of Discovery Studio. Any missing hydrogens
were also added at this stage. That way, a database of 4,076 ligands was built. Following
that, the Build Database feature of Discovery Studio was also applied, in order to gen-
erate a library, automatically indexed with sub-structure, pharmacophore feature, and
shape information to allow fast database searching. For each of the 4,076 compounds, a
maximum 255 conformations were generated. This was the final library, utilized for the
pharmacophore screening.
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3.5.2 Active phytochemicals against P07550
Screening with hypothesis 1 for protein P07550 returned 550 hits, of which 218 had
an estimated activity of less than 𝐾𝑖 = 1, 000. The list of compounds can be found in
supplementary materials S4. The first 20 phytochemicals that were estimated to have the
highest biological activity are cited in table 3.19.
Table 3.19: The 20 most active phytochemicals against P07550, as predicted by the re-
spective pharmacophore model. The chemical IDs of the compounds (CDBNO, CHEM-
LIST, CID etc.) refer to their IDs in different online databases. The common names of the
nutrients can be found, by using these IDs as queries in the online version of Nutrichem
1.0. The fit value is a measure of how well a compound maps to the pharmacophore
features. A fit value of 10 represents an ideal mapping.
Index Phytochemical ID Estimated Activity Fit value
1 CDBNO:49744 0.518744 9.49205
2 CDBNO:15590;CHEMLIST:4081603;CID:486612 0.979762 9.21588
3 CDBNO:49991 1.13665 9.15137
4 CDBNO:5346 1.15189 9.14559
5 CDBNO:35992;CHEMLIST:4076356;CID:100528 1.23077 9.11682
6 CHEM003089;CID:503732 1.28145 9.0993
7 CDBNO:54376 1.32841 9.08367
8 CID:636544 2.10969 8.88278
9 CID:16109834 2.16519 8.8715
10 CDBNO:18098;CHEMLIST:4195944;CHEMLIST:4217368;CID:145948;CID:163910 2.21789 8.86106
11 CID:637309 2.45399 8.81713
12 CDBNO:3581;CHEMLIST:4012292;CID:101712 2.5283 8.80417
13 CID:9917512 2.53903 8.80233
14 CDBNO:49745 2.83817 8.75396
15 CDBNO:42991;CHEMLIST:4253861;CID:193876 2.84968 8.7522
16 CDBNO:23164 3.25694 8.69419
17 CID:160355 3.31273 8.68681
18 CDBNO:41634 3.80728 8.62638
19 CDBNO:1223;CHEM000762;CHEMLIST:4013160;CID:164648 3.85899 8.62053
20 CDBNO:22388;CDBNO:22389;CDBNO:22390;CHEBI:53663;CHEMLIST:4021760;CID:14579 3.98236 8.60686
3.5.3 Active phytochemicals against P28222
Screening with hypothesis 1 for protein P2822 returned 322 hits, of which 135 had
an estimated activity of less than 𝐾𝑖 = 6, 000. The list of compounds can be found in
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supplementary materials S5. The first 20 phytochemicals that were estimated to have the
highest biological activity are cited in table 3.20.
Table 3.20: The 20 most active phytochemicals against P28222, as predicted by the re-
spective pharmacophore model. The chemical IDs of the compounds (CDBNO, CHEM-
LIST, CID etc.) refer to their IDs in different online databases. The common names of the
nutrients can be found, by using these IDs as queries in the online version of Nutrichem
1.0. The fit value is a measure of how well a compound maps to the pharmacophore
features. A fit value of 10 represents an ideal mapping.
Index Phytochemical ID Estimated Activity Fit value
1 CDBNO:49744 3.08888 7.1399
2 CDBNO:14395 6.40887 6.82292
3 CDBNO:39663 8.56582 6.69693
4 CDBNO:49745 9.47557 6.65309
5 CDBNO:48871 9.62313 6.64638
6 CHEMLIST:4223196;CID:4698 11.5751 6.56618
7 CHEMLIST:4231504;CID:6451137 11.5791 6.56602
8 CHEMLIST:4249758;CID:21701 14.2701 6.47527
9 CDBNO:49747 15.5695 6.43743
10 CHEMLIST:4259864;CID:52999 16.324 6.41687
11 CDBNO:20788;CID:46173976 16.3249 6.41685
12 CDBNO:43854;CDBNO:43856;CHEMLIST:4254560;CID:321311;CID:394846 17.4212 6.38862
13 CDBNO:48870 21.0255 6.30695
14 CDBNO:432 26.1479 6.21226
15 CDBNO:22584 29.8699 6.15447
16 CDBNO:13832 34.6159 6.09042
17 CDBNO:14745 34.9813 6.08586
18 CDBNO:20357 41.5108 6.01154
19 CID:11980866 42.0726 6.0057
20 CDBNO:20789 51.9176 5.91439
3.5.4 Active phytochemicals against P14416
Screening with hypothesis 1 for protein P14416 returned 2061 hits, of which 1722
had an estimated activity of less than 𝐾𝑖 = 300. The list of compounds can be found
in supplementary materials S6. The first 20 phytochemicals that were estimated to have
the highest biological activity are cited in table 3.21.
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Table 3.21: The 20 most active phytochemicals against P14416, as predicted by the re-
spective pharmacophore model. The chemical IDs of the compounds (CDBNO, CHEM-
LIST, CID etc.) refer to their IDs in different online databases. The common names of the
nutrients can be found, by using these IDs as queries in the online version of Nutrichem
1.0. The fit value is a measure of how well a compound maps to the pharmacophore
features. A fit value of 10 represents an ideal mapping.
Index Phytochemical ID Estimated Activity Fit value
1 CID:401298 0.56832 4.95381
2 CHEMLIST:4054705;CID:439221 0.573688 4.94972
3 CDBNO:34944 0.583902 4.94206
4 CDBNO:30695;CHEBI;31856;CHEBI;52513;CHEMLIST:4276090;CID:163659 0.590597 4.93711
5 CDBNO:24573;CDBNO:47429 0.600097 4.93018
6 CDBNO:11825;CID:5315931 0.635241 4.90546
7 CID:10770608 0.647479 4.89717
8 CDBNO:6005 0.655568 4.89178
9 CDBNO:19098;CHEM000755 0.656343 4.89127
10 CDBNO:50869 0.668715 4.88316
11 CDBNO:39888;CHEMLIST:4250130;CID:5380394 0.685889 4.87215
12 CDBNO:40864;CHEMLIST:4075312;CID:108011 0.717281 4.85271
13 CDBNO:45129 0.723306 4.84908
14 CDBNO:17844 0.733558 4.84297
15 CDBNO:32296;CHEMLIST:4220693;CID:471121 0.7351 4.84205
16 CDBNO:44710;CDBNO:45095;CDBNO:45097 0.737451 4.84067
17 CDBNO:56252 0.765303 4.82457
18 CDBNO:3714 0.7861 4.81292
19 CDBNO:34946;CHEMLIST:4093417;CID:442544 0.811273 4.79923
20 CID:25203645 0.812658 4.79849
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Chapter 4
Similarity-based modeling in large
scale prediction of drug-nutrient
interactions
4.1 Introduction
4.1.1 Background: In silico prediction of drug-drug interactions
Drug-drug interactions (DDIs) may occur whenever a concurrent consumption of dif-
ferent drugs is taking place, and their effects may be either synergistic, antagonistic or
coalistic (when a new effect appears, that wouldn’t have been caused by the consumption
of either drug on its own). Drug-drug interactions, much like herbal-drug interactions,
can be caused by either pharmacokinetic, or pharmacodynamic associations [37]. The
significance of DDIs becomes apparent, when we consider that 30% of all Adverse Ef-
fects (ADEs) are caused by DDIs (ADEs are one of the primary reason that drugs can
fail clinical trials). Furthermore, DDIs are regarded responsible for 0.57-4.87% of all
hospital admissions [37]. This is why, DDI evaluation is considered rather an important
aspect of Pharmacovigilance (PV), the science and activities related to detection, assess-
ment, understanding and prevention of ADEs [4]. DDIs can be evaluated in different
stages of drug development, in silico, in vitro and in vivo.
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In vitro studies usually focus on modeling the interactions of drugs with cytochrome
enzymes P450. A majority of drugs is cleared via P450 mediated metabolism, thus the
inhibition of P450 enzymes can be responsible for serious drug interactions. When con-
comitant drugs are metabolized by the same P450 enzymes, their metabolism could be
affected. However, recently, the importance of other mechanisms, such as transporters,
has also been recognized and addressed by in vitro assessments [8]. Experimental detec-
tion of ADEs using extensive in vitro safety pharmacology profiling remains challenging
in terms of cost and efficiency [25].
In vivo studies include clinical trials and further studies, after the drugs enter the mar-
ketplace. Unfortunately, DDIs may go undetected in clinical trials, because of the limited
number of participants, in comparison with the high number of drugs and possible com-
binations. Moreover, DDIs may still go undetected in post-market assessments, due to
the many different comorbidities, drug combinations and confounding factors that exist
[37].
The problem of in silico, preclinical prediction of DDIs remains an open research
challenge. Informatics has an important role in the discovery of new DDIs. Cheminfor-
matic methods, such as 2D/3D quantitative structure-activity relationships (QSAR) and
molecular docking, can be useful to predict DDIs [27]. Computational modeling has also
been used to predict CYPmetabolism–based DDIs [31]. Furthermore, data mining of sci-
entific literature, electronic medical records or adverse event databases is an emergent
approach for DDI detection [3],[24].
As part of a growing trend, many studies have also incorporated similarity based mod-
eling in identifying known, and predicting unknown DDIs. Vilar et al. [37] described a
protocol applicable on a large scale to predict novel DDIs based on similarity of drug in-
teraction candidates to drugs involved in established DDIs. The model they proposed in-
tegrated structural 2D and 3D similarity measures, with known interaction profile, target
and side-effect similarities. It was trained against a well established reference standard
database of known DDIs and used to predict new potential DDIs and their implications.
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4.1.2 Work-flow: Similarity-based prediction of psychiatric drug-
nutrient interactions
Based on the protocol presented by Vilar et al. [37], a similar procedure was carried out
to attempt a similarity-based prediction of psychiatric drugs’ interactions with nutrients
present in plant-based food. For that purpose, a reference standard database was con-
structed, incorporating information about 1763 FDA approved drugs and 69,356 DDIs.
Drug-drug interaction profile similarity, ADE similarity information, as well as 2D struc-
tural and target similarity information was gathered for the reference data set and used
to train a SVM classification model. This model was later used to predict interactions be-
tween the 64 phytochemicals and 85 drugs, classified as psycholeptics and psychoanalep-
tics, that were used to create the networks in figures 2.5 - 2.8.
4.1.3 Presentation of the SVM algorithm
SVM is an algorithm which belongs to the supervised learning models and is able to
analyze data sets and recognize patterns. It can be used for both classification and regres-
sion. This algorithm can build a model that assigns new examples into one category or
the other given a set of examples that belong to two categories. An SVM model is basi-
cally a representation of the examples as points in space, mapped so that the examples
of the separate categories are divided by a clear gap that is as wide as possible. SVM
algorithms can also perform linear and non-linear classification. There is also a big draw-
back that the SVM is only directly applicable for two-class tasks, therefore algorithms
that reduce the multi-class task to several binary problems have to be applied.
The SVM algorithms have many applications in Biology and Chemistry, especially
in Chemoinformatics. Some of these applications are the classification of objects as di-
verse as proteins and DNA sequences, microarray expression profiles and mass spectra
results. Also some other applications nowadays of SVMs are potency and active state
and similarity searching of several compounds in combination with QSAR models [14]
[33] [41].
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Figure 4.1: Maximum-margin hyperplane and margins for an SVM trained with samples
from two classes. Samples on the margin are called the support vectors [12].
4.2 Materials and Methods
The protocol that was implemented involves the generation of the reference standard
DDI database (matrix𝑀1) and the drug similarity databases (matrix𝑀2). These data are
integrated through a straightforward process consisting of the extraction of themaximum
value in each array of the matrix multiplication to generate the set of potential new DDIs
(matrix𝑀3). The generation and handling of all matrices was carried out usingMicrosoft
Excel’s VBA. Finally, the information provided by 𝑀3 is used to train an SVM model
to predict new potential interactions. In the last stage of the procedure, the performance
of the final model is assessed. This model is used to predict interactions in the database
of psychiatric drugs and phytochemicals.
4.2.1 Generation of the reference standard DDI database (matrix
𝑀1)
By using the Interax Interaction Search feature of Drugbank [16], the interactions
for 1763 FDA approved drugs were downloaded and used to construct a symmetric
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1763x1763 matrix (𝑀1), where each cell represented a drug-drug combination. If a in-
teraction was documented in Drugbank for a specific combination, the respective cell
was annotated as 1. An absence of documented interaction was annotated by 0. As the
method is based on matrix multiplication and maximization, the values in the diagonal
of the matrix needed to be set to 0 to avoid the growth of data noise caused by the ”simi-
larity” of drugs with themselves. As part of the analysis, the pharmacological or clinical
effects associated with the DDIs were also stored.
4.2.2 Generation of the drug similarity databases (matrix𝑀2)
The matrices 𝑀2 were also symmetrical 1763x1763, where this time, each cell con-
tained similarity information about the respective combination of drugs. Four different
similarity types were evaluated, and thus, four different𝑀2 matrices were constructed.
Similarity based on 2D structural fingerprints
The basic 2Dmolecular structure fingerprint technique consists of representing amolecule
as a bit vector that codifies the presence or absence of different substructural or phar-
macophoric features in each bit position. Essentially a fingerprint is a codified vector
version of the 2D molecular structure. There are different types of systems for codifying
fingerprints, however in the present method MACCS (for Molecular Access System)
structural keys were used [23]. As a way to represent a sparse binary vector, only the po-
sitions codifying the fragments present in the molecule are stored in the final fingerprint
[37].
For each drug, a MACCS fingerprint was calculated, using Python 2.7 and the open
source software OpenBabel. Following the instructions in the protocol of Vilar et al. [37],
a Python script was written, that given a SMILES.txt list of tab-delimited chemical IDs
and SMILES codes, e.g., such as;
CHEMBL973 C\C(=C(/C#N)\C(=O)Nc1ccc(cc1)C(F)(F)F)\O
CHEMBL1382 CC(C)N(CC[C@H](c1ccccc1)c2cc(C)ccc2O)C(C)C
it calculated all MACCs fingerprints for the drugs. The fingerprint type can be changed
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by specifying a different string for FINGERPRINT. Available fingerprints are FP2, FP3,
FP4 and MACCS [37].
In order to calculate the similarity between two fingerprints, belonging to two different
drugs, the script went on to calculate the Tanimoto coefficient for each pair. The TC is
also known by the term Jaccard index. The TC can adopt values in the range between 0
(maximum dissimilarity) and 1 (maximum similarity). The TC between fingerprints A
and B is defined as [43]:
𝑇𝐶 = 𝑁𝐴𝐵𝑁𝐴 +𝑁𝐵 +−𝑁𝐴𝐵
(4.1)
where , 𝑁𝐴 and 𝑁𝐵 is the number of features present in fingerprints 𝐴 and 𝐵, respec-
tively, and𝑁𝐴𝐵 is the number of features present in common to both fingerprints𝐴 and
𝐵.
This script generates an output TC_results.csv file containing all pairwise TCs above
a specified cutoff (T_CUTOFF, default 0.00).
Script 4.1: Using Python to calculate molecular fingerprints and TC between all drug
pairs with Open Babel
# -*- coding: cp1252 -*-
import csv
import subprocess
import re
import os
T_CUTOFF = 0.00
FINGERPRINT = "MACCS"
FILENAME = "SMILES.txt"
input_read = open(FILENAME,"r")
input_temp = open("temp_smi_file.txt","w")
input_dict = dict()
for line in input_read:
newline =line.split()
id = newline[0]
smiles = newline[1]
input_dict[id] = smiles
input_temp.write("%s\t%s\n" %(smiles, id) )
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input_read.close()
input_temp.close()
f = open("TC_results.csv", "w")
writer = csv.writer(f)
writer.writerow(["chemical1", "chemical2", "TC"])
for chemical1 in input_dict:
babel_command= "obabel -ismi -: ￿ % s ￿ temp_smi_file.txt -ofpt -xf%
s" %(input_dict[chemical1], FINGERPRINT)
output = subprocess.Popen(babel_command , shell=True, stdout=
subprocess.PIPE, stderr=subprocess.PIPE)
TC_list = []
n=0
while True and n<1000000:
n=n+1
line = output.stdout.readline()
#line example: ￿ >CHEMBL1382 Tanimoto from CHEMBL973 = 0.2 ￿
if line != "":
newline = re.split(">|=", line)
#newline: [ ￿ , "CHEMBL1382 Tanimoto from CHEMBL973 ", "
0.2\n"]
#indices: [0] [1] [2]
if len(newline) > 2:
id_catcher = newline[1].split()
chemical2 = id_catcher[0]
TC = float(newline[2].strip())
TC_list.append((chemical2 , TC))
else:
break
for chemical2 ,TC in TC_list:
if TC > T_CUTOFF and chemical1 != chemical2:
writer.writerow([chemical1 , chemical2 , TC])
else:
writer.writerow([chemical1 , chemical2 , 0])
f.close()
os.remove("temp_smi_file.txt")
The calculated Tanimoto coefficients for all pairs of drugs were then transformed into
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Figure 4.2: Workflow of the steps carried out during the calculation of Tanimoto coeffi-
cients for target profile similarity. Graph adapted from Vilar et al. [37].
the symmetrical 𝑀2 matrix, where each element (𝑖, 𝑗) contained the TC between the
drug in row 𝑖 and the drug in column 𝑗. All diagonal values were again set to 0.
Similarity based on target profile fingerprints
A second𝑀2 matrix was generated, by evaluating the similarity of drugs, in respect to
whether they target the same proteins. For that purpose all the targets, enzymes, carriers,
transporters for each FDA approved drug were downloaded from Drugbank [16]. Next,
a table was constructed, where each row represented a drug and each column represented
one of the 1990 protein targets. Each cell (𝑖, 𝑗) was marked as 1 if the drug 𝑖 was found
to target protein 𝑗. This information was then coded into ”target profile fingerprints” in
the following manner; Each different protein was assigned a number, from 1-1990. Then,
values 1 in each cell in the matrix were substituted with their column’s target number.
As a result, each drug in the matrix was matched to a serial number (”fingerprint”), com-
prising of a series of numbers, corresponding to the proteins it targets. This procedure is
depicted in figure 4.2.
These target profile fingerprints were used to calculate Tanimoto coefficients for each
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pair of drugs, using Python (script 4.2) and following the instructions of Vilar et al. [37].
The input of this script is a M2input.txt file with the following format:
id1, 1 3 45 234 237
id2, 4 5 355 546
id3, 1 2 3 87 1080
The pairwise TCs were then exported in the M2_TC_results.txt and, eventually, trans-
formed into yet another symmetrical𝑀2 matrix, where each element (𝑖, 𝑗) contained the
target similarity TC, between the drug in row 𝑖 and the drug in column 𝑗. All diagonal
values were again set to 0.
Script 4.2: Using Python to calculate TCs between fingerprints
# -*- coding: utf-8 -*-
import os
import sys
from collections import defaultdict
def tanimoto(a, b):
if len(a)==0 and len(b)==0:
return 0
else:
return len(a&b)/float(len(a|b))
fingerprints = defaultdict(set)
FILENAME=open("M2input.txt","r")
sys.stdin=FILENAME
OUTPUTFILE=open("M2_TC_results.txt","w")
sys.stdout=OUTPUTFILE
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for line in sys.stdin:
identifier , fpt = line.split(",")
fingerprints[identifier] = set(fpt.split())
for id1 in sorted(fingerprints.keys()):
for id2 in sorted(fingerprints.keys()):
if id1 > id2:
continue
similarity = tanimoto(fingerprints[id1], fingerprints[id2])
print >> sys.stdout, "%s\t%s\t%f" % (id1, id2,similarity)
OUTPUTFILE.close()
Similarity based on interaction profile fingerprints (IPFs)
Another way, proposed by Vilar et al. [37], to evaluate the similarity between two
drugs was by comparing their interaction profiles. More specifically, two drugs were
considered similar if they interacted with the same drugs in the initial 𝑀1 reference
interaction matrix. For that purpose, a newmatrix was constructed, similar to𝑀1, where
every row and column represented one of the 1763 FDA approved drugs, and known
interactions between drugsweremarkedwith 1 in the corresponding cells. The procedure
following that was identical to the one carried out in the evaluation of target similarity
profiles. Each column was annotated with a position number, which was later used to
substitute the values 1 in each particular column. In that manner, a serial number for each
rowwas generated (”interaction profile fingerprint or IPF”). The IPFs were, then, used as
input for script 4.2, in order to calculate the new Tanimoto coefficients that measured the
interaction profile similarity between the pairs of drugs. Finally, a third𝑀2 matrix was
built, where each element (𝑖, 𝑗) contained the interaction profile similarity TC, between
the drug in row 𝑖 and the drug in column 𝑗. Diagonal values were again set to 0, as before.
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Similarity based on ADE profile fingerprints
Moreover, the similarity between drugs was evaluated based on their adverse effect
profiles [37]. Information about drug ADEs was downloaded from the SIDER database
[26]. A matrix was then built, where each row represented one of the 1763 drugs and
each column one of 5059 side-effects. ADE profile fingerprints and pairwise TCs were
then calculated, the same way, as for interaction and target profiles. This way the fourth
𝑀2 matrix was generated, where each element (𝑖, 𝑗) contained the ADE similarity TC,
between the drug in row 𝑖 and the drug in column 𝑗. Once again, diagonal values were
set to 0.
4.2.3 Generation of the new set of potential DDIs (matrix𝑀3)
In this stage of the protocol, the two databases M1 and M2 are integrated, in the way
that Vilar et al. [37] proposed. The objective here is to obtain the matrix M3 that con-
tains all the possible scored DDIs through the multiplication of 𝑀1 by 𝑀2, retaining
only the highest value in the array multiplication in each cell. This procedure is illus-
trated in figure 4.3. The resulting 𝑀3 was not symmetric (since the action performed
was not conventional multiplication), and had to be converted into a symmetric matrix,
by keeping the highest value on either side of the diagonal. Vilar et al. [37] claim it is
also possible to associate clinical effects with the new DDIs, in the way illustrated in
figure 4.4. As four different ways of similarity were examined, the obtained result were
four different𝑀3 matrices. In effect, for each drug-drug combination, four TC variables
were assigned.
4.2.4 Training and assessment of the SVM model
The information extracted from the𝑀3 matrices amounted to 1,553,203 unique drug-
drug combinations, each described by four TC variables. Moreover, 69,356 of these
combinations were noted as established interactions, which were recorded in the initial
reference database. A Support VectorMachine classification algorithmwas implemented
in Molegro Data Modeller 2013.3.0 [6], by using a subset of 50,322 of drug-drug combi-
nations (10,918 known interactions). The selection was done, by using a N dimensional
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Figure 4.3: Generation of the new set of potential DDIs (matrix𝑀3). Vilar et al. [37].
Figure 4.4: DDI effect linkage: list of DDIs extracted from 𝑀3 are associated with the
initial source in𝑀1 and with the clinical or pharmacological effects caused by the inter-
action.). Vilar et al. [37].
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grid method, in order to remove redundant, overlapping data. The SVM was trained by
using as a target variable a boolean (1 or 0) variable that indicated whether a data point
represented a well established, initial interaction. The Tanimoto coefficients of IPFs,
targets, ADEs and structural fingerprints were used as independent variables. A larger
subset of training data could have been used, however, due to computational time restric-
tions, and the good performance of the model generated, this was not attempted in the
present analysis.
The model generated had an accuracy of 80.83%. Its precision, recall and f-measure
was 82.15%, 96.48% and 88.74% , respectively, in predicting an absence of interaction
(0). Using 5-fold validation, the corresponding accuracy was 80,76%, while precision,
recall and f-measure were calculated as 82.12%, 96,42% and 88.70%. There results dis-
play an adequate capability of the SVM to classify the data. Furthermore, over-fitting
the data, is most likely avoided, since the 5-fold validation did not affect significantly
the accuracy of the model.
4.2.5 Building the test set of phytochemicals and psychiatric drugs
A test database of phytochemicals and psychiatric drugs was constructed in an iden-
tical way as the training database. A𝑀1 149x149 matrix was generated for the 64 phy-
tochemicals and 85 psychiatric drugs. Known interactions were sought for in Drugbank
for the psychiatric drugs, as well as the phytochemicals that were already documented as
nutraceuticals. For example, Epigallocatechin and Catechin may be found in Drugbank
under the code DB01266 (Sinecatechins), an approved botanical drug product for topical
use. Structural TCs were calculated, usingMACCS fingerprints, similarly to the training
set. In order to calculate target profile fingerprints, the information about the common tar-
gets that was obtained from Drugbank and NutriChem, in the first part of this paper, was
utilized (Chapter 2.). Finally, ADE information was obtained from SIDER, whenever
it was available. Unfortunately, this information was scarce in the case of phytochemi-
cals. The𝑀3 matrices were calculated the same way, as before, resulting in a data set of
11,026 unique combinations, each described by 4 similarity measures (TCs). Table 4.1
lists the phytochemicals and psychiatric drugs that were studied.
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Table 4.1: List of the 64 phytochemicals and 85 psychiatric drugs
Phytochemicals Psychiatric drugs
(-)-Epigallocatechin Iso-Ompa DB00176 DB00734 DB01623
(+)-Catechin Kaempferol DB00182 DB00752 DB01624
(S)-Laudanosine Liquiritin DB00215 DB00780 DB04599
2,3-Butanedione Luteolin DB00246 DB00805 DB04820
9-Amino-1,2,3,4-Tetrahydroacridine Myricetin DB00289 DB00831 DB04821
Alpha-Aminoadipic Acid N-Acetylcysteine DB00321 DB00843 DB04832
Aminooxyacetate Naringenin DB00334 DB00850 DB04836
Apigenin Nicotine DB00363 DB00875 DB04842
Aporphine Nicotinic Acid DB00370 DB00933 DB04896
Arecoline Nordihydroguaiaretic Acid DB00382 DB00934 DB04946
Atenolol Papaveraldine DB00391 DB00989 DB06144
Caffeine Papaverine DB00408 DB01043 DB06148
Carbachol Paroxetine DB00409 DB01063 DB06216
Cortisone P-Benzoquinone DB00420 DB01104 DB06288
Daidzein Phenylbutazone DB00422 DB01142 DB06594
Dihydrocapsaicin Propidium Iodide DB00450 DB01149 DB06684
Donepezil Quercetin DB00458 DB01151 DB06700
Epicatechin Gallate Rivastigmine DB00472 DB01171 DB08815
E-Piceatannol Rutoside DB00476 DB01175 DB08996
Eriodictyol Salsolinol DB00477 DB01224 DB09014
Falcarindiol Sanguinarine DB00490 DB01238 DB09016
Fisetin Serotonin DB00502 DB01239
Flavanone Sodium Nitroprusside DB00508 DB01242
Galangin Spermine DB00540 DB01247
Glutamic Acid Taxifolin DB00543 DB01267
Harmine Thapsigargin DB00557 DB01356
Hesperetin Tramadol DB00623 DB01403
Higenamine Trifluoperazine DB00656 DB01608
Hydrobenzoin Tryptamine DB00674 DB01614
Hyperin Tyramine DB00679 DB01618
Isatin Wogonin DB00715 DB01621
Isoliquiritigenin Xanthotoxin DB00726 DB01622
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4.3 Results
When implementing the SVM trained model in generating a prediction for the test set
of phytochemicals and psychiatric drugs, the following results were obtained. The ac-
curacy, precision, recall and f-score for this model were 94.55%, 98.56%, 94.94% and
96.72% respectively. The confusion table can be found in table 4.2. It was, therefore, ob-
served that the discerning ability of the SVM model for the data set of phytochemicals
and psychiatric drugs was very high. Figure 4.5, illustrates the interaction network. This
network consists only of the initial interaction data (values ”1”, extracted from Drug-
bank), and the predicted interactions (values ”1”, from the SVM model), between drugs
and phytochemicals.
Table 4.2: Confusion matrix for the interaction predictions of the SVMmodel on the test
set of phytochemicals and psychiatric drugs.
Predicted non interacting Predicted interacting SUM
Non interacting 8849 472 9321
Interacting 129 1576 1705
SUM 8978 2048 11026
According to the information supplied by NutriChem, Paroxetine, Tramadol and Tri-
fluoperazine are compounds that can be found in white-pepper, poppy-seed and garlic,
respectively. Donepezil is a constituent of peach fruit, whereas Rivastigmine may be
found in cashew nuts. Caffeine, on the other hand is the well known constituent of tea
and coffee, that may also be found in cocoa, Typha angustifolia, Caulophyllum robustum,
the California fawn lily, Ginkgo biloba and Bracken fern. For Xanthotoxin, the network
of plant-based food that is cited by NutriChem is presented in figure 4.6. Carbachol may
be found in ginger, Nepeta cataria, Panax ginseng and Viburnum prunifolium. Moreover,
Papaverine is found in poppy-seed, and the network for Nicotine is presented in figure
4.6. Finally, Atenolol may be found in nutmeg and Cortisone is a constituent of sprouted
lentil [21].
77
Chapter 4. Similarity-based modeling in large scale prediction of drug-nutrient interactions
Figure 4.5: Interactions between psycholeptic and psychoanaleptic drugs (Drugbank
code names used) and phytochemicals. Data extracted from Drugbank and predicted
by the SVM model.
Figure 4.6: Plant-based food that contains Xanthotoxin and Nicotine[21]. Edge width
indicates the number of references cited in NutriChem for each association.
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Discussion
Characteristics, limitations and points for improvement of the pharmacophoric
screening approach
Because pharmacophoric screening is only a preliminary method in the discovery of
relevant compounds, it is meant to be used as a coarse sieve; not too precise, however
a high recall of true positives is usually desired. In that sense, the results of pharma-
cophoric screening are usually large aggregations of molecules that are later filtered
based on additional criteria. The models that were built in the present analysis, and used
to screen NutriChem for ligands that would bind with proteins P07550, P28222 and
P14416, were characterized by mediocre results in recalling true positive hits and higher
precision. These qualities would mean that many true hits could be missed, even in the
initial stage of the discovery process. Moreover, the models were not proven to be very
robust when tested against different validation sets, which could indicate an over-fitting
of the models on the training data sets.
As a means to generate improved pharmacophore models, efforts should be made in
improving the quality of the training sets. This could be done by docking simulations or
literature searches to reveal in which specific binding pockets of the protein each com-
pound binds, and filter out only these compounds that bind in the same pocket as the
psychiatric drugs. Special care should be given, also, to filtering out only the specific
isomers of a compound that bind with the protein. In the effort to build a robust phar-
macophore model, the structure-based approach of the HypoGen algorithm could be
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integrated with receptor-based approaches. For example, the HypoGen algorithm could
be enhanced with excluded volume restrictions, to avoid compounds that cannot bind
due to steric obstructions. Alternatively, the pharmacophore models that were generated
could be compared and integrated with receptor-based pharmacophore models, since
complexes of ligands bounds with the proteins are available in PDB.
Characteristics, limitations and points for improvement of the similarity-based pre-
diction model
The similarity-based approach for the prediciton of drug-nutrient interactions had sev-
eral significant limitations and caveats. Although the model displayed good robustness
in hold-out validation and against the test set of phytochemicals/psychiatric drugs, it’s
performance in predicting new, potential interactions, that were not documented in the
initial reference set, is limited. The approach that was adopted by Vilar et al. [37] de-
pends vastly on the quality of the initial reference standard database, and expands upon
the well-established DDIs, known in the literature. Therefore, in cases where limited in-
formation is available about established interactions, as is the case with newly marketed
drugs, or phytochemicals, the performance of the model is hindered. A second caveat
is that the protocol introduced by Vilar et al. [37] was designed for use on large-scale
analysis. Therefore, it is not suitable for detection of small variations in the similarity
measure that can strongly affect the biological effects of drugs. Moreover, it is expected
that different similarity measures might be more suitable to detect interactions in differ-
ent categories of drugs.
A more comprehensive similarity-based approach to predict nutrient-drug interactions
is one that should be better tailored to the available information from the literature, con-
cerning phytochemicals. In the case of compounds found in plant-based food, only par-
tial (and thus biased) information is available to be used in the calculation of IPF sim-
ilarity or ADE similarity. Therefore, a more solid approach to this particular problem
could use only target and structural similarity measures in order to create a good clas-
sification model. Moreover, the training reference data set could be better designed to
involve phytochemicals, as well as drugs. Due to the nature of the protocol implemented
by Vilar et al. [37], a larger-scale approach, that would incorporate inter-class interac-
80
tions of phytochemicals with many different ATC categories of drugs, would be better
suited for analysis with a similarity-based model. Different similarity measures could
also be employed, such as 3D structural similarity, provided that available information
could be found in the literature.
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